

Review

Not peer-reviewed version

Twelve Hallmarks, One Target: The Metadichol® Approach to Systems-Level Aging

[Palayakotai R. Raghavan](#) *

Posted Date: 8 September 2026

doi: 10.20944/preprints202609.0550.v1

Keywords: hallmarks of aging; Metadichol; policosanol; vitamin D receptor inverse agonist; sirtuins; telomerase; nuclear receptors; cellular reprogramming; Yamanaka factors; longevity; FOXO; mTOR; systems biology; anti-aging therapeutics



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC, OpenAlex.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Twelve Hallmarks, One Target: The Metadichol® Approach to Systems-Level Aging

Palayakotai R. Raghavan

Nanorx Inc, PO box 131, Chappaqua NY 10514, USA; raghavan@nanorxinc.com

Abstract

Background: The interconnected nature of aging mechanisms presents a fundamental challenge to therapeutic intervention: single-target approaches yield limited benefits when aging pathways operate as an integrated network. Current interventions—resveratrol, metformin, rapamycin, and NAD⁺ boosters—each address only 1–3 molecular targets, leaving most aging processes unmodulated. Metadichol, a nano-emulsion of naturally occurring long-chain alcohols (policosanols), functions as an inverse/protean agonist of the vitamin D receptor (VDR) capable of modulating over 2,300 genes and activating all 49 known nuclear receptors. This review examines the evidence supporting Metadichol’s capacity to simultaneously address all twelve hallmarks of aging. **Methods:** We synthesized findings from published in vitro cell culture studies, gene expression analyses, and reports examining Metadichol’s effects on aging-associated genes and pathways. A comparative analysis was conducted against established anti-aging interventions to evaluate relative target coverage and mechanism breadth. **Results:** In the studies reviewed here, Metadichol modulates targets spanning all twelve hallmarks of aging: (1) genomic stability through TP53 modulation and altered expression of multiple DNA-repair-annotated genes; (2) telomere maintenance via 16-fold TERT upregulation and 4–10× Klotho induction; (3) epigenetic homeostasis through coordinate upregulation of all seven sirtuins (SIRT1–7, 3–15 fold); (4) proteostasis via SIRT1→FOXO-mediated autophagy enhancement; (5) nutrient sensing through BCAT1 inhibition (3000× more potent than gabapentin) and mTOR modulation; (6) mitochondrial function via PGC-1α upregulation and mitochondrial sirtuin activation; (7) senescence regulation through Klotho→TP53 axis modulation and TLR pathway regulation; (8) stem cell rejuvenation via induction of Yamanaka factors (OCT4 ↑19.6×, KLF4 ↑8×, SOX2 ↑6.9×) and GDF11 upregulation; and (9) intercellular communication through TNF-α/NF-κB downregulation and circadian clock gene restoration. The three expanded hallmarks are addressed in parallel: (10) disabled macro autophagy through mTOR suppression and SIRT1→FOXO-driven autophagy gene induction; (11) chronic inflammation (inflammaging) through NF-κB/TNF-α and HMGB1 suppression coupled with Klotho and FOXP3/Treg induction; and (12) dysbiosis through VDR-mediated regulation of antimicrobial-peptide expression and intestinal-barrier integrity. Comparative analysis reveals Metadichol targets 13+ molecular pathways versus 1–3 for conventional interventions, with a favorable safety profile (GRAS status, no carcinogenicity in 18–24 month rodent studies). These transcriptional changes are corroborated at the protein level by Western blot for the genes examined; functional and in vivo validation is the principal remaining step (see Limitations). **Conclusions:** Metadichol represents a shift from single-target pharmacology toward systems-level aging intervention. Its mechanism—VDR inverse/protean agonism coupled with broad nuclear-receptor network activation—enables simultaneous modulation of interconnected aging pathways that are proposed to operate synergistically; the extent of functional synergy is a defined objective for in vivo work. The convergence of pan-sirtuin activation, telomerase induction, non-viral reprogramming-factor expression, and anti-inflammatory effects in a single food-derived compound—corroborated at both mRNA and protein levels—positions Metadichol as a leading candidate for prioritised clinical investigation.

Keywords: hallmarks of aging; Metadichol; policosanol; vitamin D receptor inverse agonist; sirtuins; telomerase; nuclear receptors; cellular reprogramming; Yamanaka factors; longevity; FOXO; mTOR; systems biology; anti-aging therapeutics

1. Introduction

Aging represents the primary risk factor for most human diseases, including cancer, cardiovascular disease, neurodegenerative disorders, and metabolic dysfunction.[1]
Table 1 shows a conceptual framework identifying twelve hallmarks of aging that represent common denominators across diverse organisms.[2] These hallmarks include: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. More recently the expanded framework includes three additional hallmarks: disabled macro autophagy, chronic inflammation, and dysbiosis.

Table 1. The Twelve Hallmarks of Aging.

1. Genomic Instability	2. Telomere Attrition	3. Epigenetic Alterations	4. Loss of Proteostasis
5. Disabled Macro autophagy	6. Deregulated Nutrient Sensing	7. Mitochondrial Dysfunction	8. Cellular Senescence
9. Stem Cell Exhaustion	10. Altered Intercellular Communication	11. Chronic Inflammation	12. Dysbiosis

A major challenge in aging research is the interconnectedness between these hallmarks, suggesting that effective interventions must address multiple pathways simultaneously.[3,4] Traditional pharmaceutical approaches targeting single molecular entities have shown limited efficacy in extending health span. Current anti-aging interventions such as resveratrol (primarily SIRT1 activation), metformin (AMPK/mTOR modulation), rapamycin (mTOR inhibition), and NAD+ boosters (sirtuin substrate provision) each address only 1-3 molecular targets, leaving many aging pathways unaddressed.[5–9]
Metadichol® is a nano-emulsion of long-chain alcohols (policosanols) found naturally in foods including rice, sugar cane, wheat, and peanuts. [10] Metadichol functions as an inverse/protean agonist of the vitamin D receptor (VDR), modulating nuclear receptor signaling and affecting over 2,300 genes. [11,12] This review examines the evidence supporting Metadichol’s capacity to address each hallmark of aging through its comprehensive gene regulatory mechanisms and compares its multi-target approach to existing interventions.

The Hallmarks of Aging: Mechanisms and Metadichol’s Interventions

2.1. Genomic Instability

Genomic instability represents a primary hallmark characterized by the accumulation of genetic damage throughout life. [2] Nuclear and mitochondrial DNA are continuously subjected to exogenous agents (radiation, chemicals) and endogenous threats (replication errors, reactive oxygen species). The tumor suppressor p53 (TP53) serves as the guardian of the genome, coordinating DNA

damage response, cell cycle arrest, and apoptosis. [13–15] PARP1 plays critical roles in DNA repair and chromatin remodeling during aging.[16,17]

Metadichol's Modulation: Metadichol treatment induces TP53 modulation that is associated with altered expression of ~600 master regulatory genes involved in DNA repair and genomic maintenance. [18] Studies show that Metadichol upregulates DNA-repair transcripts in parallel with nuclear-receptor pathway activation. Additionally, Metadichol increases Vitamin C availability — via GULO-dependent synthesis in GULO-competent species and via ascorbate recycling in humans (see Section 10) — providing antioxidant protection of DNA from oxidative damage. [19] Age-associated impairment of DNA double-strand break repair is counteracted through SIRT6 activation.[20]

2.2. Telomere Attrition

Telomeres are repetitive nucleoprotein sequences at chromosome ends that shorten with each cell division. Progressive telomere shortening leads to chromosomal instability, cellular senescence, and stem cell exhaustion. [21,22] Telomerase (TERT), the enzyme responsible for telomere maintenance, is absent or insufficiently active in most somatic cells. Telomere dysfunction contributes to age-related diseases across multiple organ systems.[23]

Metadichol's Modulation: Metadichol treatment increases telomerase (TERT) mRNA expression by 16-fold at picomolar concentrations. [24] Western blot analysis confirmed telomerase protein expression at replacement levels. TERT activation has been shown to target DNA methylation and multiple aging hallmarks simultaneously. [25] Klotho upregulation (4-10×) further supports telomere maintenance. [26] SIRT6 activation, which is essential for DNA double-strand break repair in long-lived species, is induced 3-15-fold by Metadichol treatment.[4,18]

2.3. Epigenetic Alterations

Aging is accompanied by alterations in DNA methylation patterns, histone modifications, and chromatin remodeling. [28] The sirtuin family of NAD⁺-dependent deacetylases (SIRT1-7) plays crucial roles in epigenetic regulation, with activity declining with age. [29–31] NAD⁺ serves as an essential cofactor for sirtuin activity, and its cellular levels decline with aging.[32,33]

Metadichol's Modulation: A notable finding is Metadichol's ability to increase expression of all seven sirtuin genes (SIRT1-7) (Figure 1) by 3- to 15-fold in human dermal fibroblasts, with protein-level (Western blot) confirmation. [18] This is unusual because most known sirtuin activators (including resveratrol) are specific for SIRT1 only. [34] SIRT1, SIRT6, TERT, Klotho, PGC1A, P53 and FOXO1 together play critical roles in aging-related diseases. [35] SIRT3/6 are essential in fighting fibrosis and aging. [3] Figure 1 shows fold expression changes of fibroblast cells activated by Metadichol; additionally, FOX/KLF transcription-factor genes are comprehensively upregulated (summarised in Section 2.3), further supporting epigenetic homeostasis.[41,42]




Figure 1. Sirtuins and other anti-aging genes.

LINE-1 Retrotransposon Suppression: A mechanistically important but underappreciated consequence of SIRT6 upregulation is the silencing of LINE-1 (L1) retrotransposons. LINE-1 elements constitute approximately 17 % of the human genome; ~100 full-length copies remain retro transposition-competent and are normally suppressed by SIRT6-dependent H3K9me3 heterochromatin at their promoters. As SIRT6 activity declines with age, heterochromatin relaxes, LINE-1 elements transcribe, and their ORF2-encoded reverse transcriptase synthesizes cytoplasmic cDNA – a process mechanistically indistinguishable from retroviral replication. The innate immune system responds accordingly: cytoplasmic L1-derived DNA activates the cGAS–STING pathway to produce type I interferons (IFN- α/β), while L1 RNA secondary structures trigger MDA5/RIG-I – the same double-stranded RNA sensors that detect influenza and SARS-CoV-2. The result is a chronic, sterile ‘viral mimicry’ state that amplifies the SASP, feeds inflammaging, and contributes to immunosenescence in the absence of any pathogen – a mechanism now directly documented in senescent human cells. [38–40] Notably, nucleoside reverse-transcriptase inhibitors (NRTIs) – drugs designed to block HIV reverse transcriptase – also inhibit L1 ORF2p, suppress cGAS–STING signalling, reduce the SASP, and extend healthy lifespan in aged mice, providing pharmacological validation of the axis. [39] Metadichol’s 4.26-fold induction of SIRT6 (Figure 1, 100 ng/mL) is therefore predicted to restore the repressive heterochromatin that keeps LINE-1 silent, reducing cytoplasmic cDNA burden, attenuating cGAS–STING-mediated type I interferon production, and dampening the sterile inflammatory signal at its source. This LINE-1/SIRT6 axis represents a direct upstream mechanism through which Metadichol’s pan-sirtuin activation contributes to the c-GAS–STING suppression already documented in the MiDAS loop (Section 2.6) and to the broader anti-inflammaging program described in Section 2.11.


- SIRT1 and P53 interact to regulate DNA repair and apoptosis. SIRT1 can deacetylate TP53, which enhances the transcriptional activity of the p53 protein and increases apoptosis.
- SIRT6 also interacts with TP53 to regulate DNA repair and apoptosis. However, SIRT6 deacetylates TP53, reducing the transcriptional activity of the P53 protein and decreasing apoptosis.
- Both SIRT3 and SIRT5 play roles in regulating cellular metabolism and mitochondrial function. SIRT3 has been shown to deacetylate and deactivate SIRT5. On the other hand, the SIRT5 protein can deacetylate and activate enzymes involved in fatty acid metabolism.

- TP53 has been shown to transcriptionally repress the expression of TERT, which is involved in maintaining the length of telomeres. Additionally, TERT can interact with p53 to regulate apoptosis and the DNA damage response.
- FOXO1 can be deacetylated and activated by SIRT1, leading to an increase in the expression of genes involved in metabolism and the cellular stress response (Figure 7).

Across the 1 pg/mL to 100 ng/mL series in human PBMCs, all seven sirtuins were induced together with the principal anti-aging effectors, the response in most cases increasing with dose. The largest were **SIRT3 (15.67-fold)** and **FOXO1 (15.35-fold)** at 100 ng/mL, with **PGC1A** showing the opposite profile and peaking at the lowest dose tested (11.08-fold at 1 pg/mL). SIRT1 rose 6.92-fold, SIRT2 5.17-fold, SIRT6 4.26-fold and SIRT7 3.68-fold; SIRT4 and SIRT5 responded more modestly (2.91- and 3.16-fold). Alongside these, TERT reached 4.29-fold, p53 4.11-fold and Klotho 3.12-fold. The SIRT6 value is the one that carries the LINE-1 argument developed above. The full dose-response matrix for this panel is reported in our earlier study of sirtuin induction in somatic and cancer cells [18] and is not reproduced here.

Metadichol engages the **FOX** and **KLF** transcription-factor families in their entirety rather than selected members, which is the pattern expected of upstream regulator engagement. Within the FOX family in PBMCs the response is strongly biphasic: most members are suppressed at 1 ng/mL and recover or exceed baseline at 100 ng/mL. FOXA1 (7.39-fold), FOXH1 (7.22-fold), FOXA3 (6.98-fold), FOXB1 (6.79-fold), FOXA2 (6.57-fold) and **FOXO1 (8.74-fold)** peak at the top dose, whereas FOXD2 (6.36-fold), FOXG1 (6.26-fold) and FOXD4 (4.67-fold) peak at 1 pg/mL and FOXI1 (5.73-fold) at 100 pg/mL. A minority, including FOXL1 and FOXL2, remain below control throughout. The KLF family responds over a narrower range, with KLF8 (4.99-fold) and KLF9 (3.02-fold) highest at 1 pg/mL, KLF15 elevated at both extremes of the series (2.90- and 2.14-fold), and KLF17 rising only at 100 ng/mL (2.47-fold); KLF4, the Yamanaka factor, peaks at 1 ng/mL (1.56-fold). Gene-by-gene fold-regulation values for both families across the dose series are given in our dedicated reports on the FOX [41] and KLF [42] networks, to which the reader is referred; the directional summary above is sufficient for the argument made here.

The convergent activation of Sirtuins, FOXOs, and KLFs by a single compound represents a paradigm shift in anti-aging pharmacology. These three families form an integrated longevity network:



Metadichol’s mechanism—likely through VDR modulation and downstream transcriptional cascades—enables coordinated activation rather than isolated pathway targeting. This distinguishes it from single-target interventions such as resveratrol (SIRT1) or rapamycin (mTOR).

2.4. Loss of Proteostasis

Proteostasis involves the integrated cellular machinery responsible for protein synthesis, folding, trafficking, and degradation. Aging compromises the proteostasis network, leading to

protein aggregation implicated in neurodegenerative diseases. [43,44] Heat shock proteins play critical roles in maintaining proteostasis during aging.[45]

Metadichol’s Modulation: Through SIRT1→FOXO activation (**Figure 2**), Metadichol enhances autophagy pathways. [46,47] mTOR modulation shifts cellular metabolism toward catabolic processes that clear damaged proteins. SIRT6→NF-κB inhibition reduces proteotoxic stress from inflammatory signaling (Figure 3).[48–50]





Figure 2. Metadichol induces nuclear receptors and Sirtuin-anchored circadian regulation. Purple edges denote Metadichol-driven induction of nuclear receptors (RORα, RXRB/G/A, Rev-ErbAα, HNF4A, PPARG) and of SIRT1/SIRT6; blue edges denote Sirtuin regulation of the circadian clock (BMAL1, CLOCK, CRY1) and interaction with PGC-1α.



Axes described in Section 2.4: SIRT1 → FOXO-driven autophagy, mTOR-modulated catabolic protein clearance, and SIRT6 → NF-κB suppression of proteotoxic inflammatory stress.

Figure 3. Metadichol restores proteostasis through three coordinated axes: SIRT1→FOXO-driven autophagy that clears damaged proteins, mTOR-modulated catabolic protein turnover, and SIRT6→NF-κB suppression of proteotoxic inflammatory stress — supported in parallel by the HSF1/SIRT1-anchored heat-shock-protein chaperone network.

Direct evidence for chaperone-network regulation. Unpublished results now show that Metadichol acts directly on the chaperone machinery itself, not only on the degradative arm of proteostasis. In primary human peripheral blood mononuclear cells treated for 24 h across 0.1 pg/mL–100 ng/mL, Metadichol coordinately induced all 22 core genes of the heat shock protein (HSP) / proteostasis network. [51] The response spanned every functional module of the chaperonome rather than a single family: the master regulators (HSF1, HSF2, SIRT1); the ATP-dependent HSP70 machine (HSPA1A, HSPA8, HSPA14, HSPH1, DNAJB1, BAG3); the HSP90 machine (HSP90AA1, HSP90AB1, CDC37, STIP1); the ATP-independent small-HSP holdases (HSPB1, HSPB5); the mitochondrial arm (HSPA9, HSPD1, HSPE1, TRAP1, DNAJA3); and the endoplasmic-reticulum arm (HSPA5/BiP, HSP90B1/gp96); each module’s chaperone function and its relevance to aging are summarized in Table 2. Peak induction ranged from 1.34× (HSPA8) to 4.00× (DNAJA3), with strong responses for the disaggregase HSPH1 (3.20×), the HSP90 organizing co-chaperone STIP1/HOP (3.17×), the ER chaperones BiP (2.71×) and gp96 (2.61×), and the stress-inducible HSPA1A (2.57×) (Figure 4).




Figure 4. Metadichol induces all 22 genes of the HSP / proteostasis network in human peripheral blood mononuclear cells. Peak fold change versus untreated control is shown for each gene, colored by chaperone module (regulators; HSP70 machine; HSP90 machine; small HSPs; mitochondrial arm; ER arm), with the concentration producing the peak annotated beside each bar. Every gene is induced above the control baseline (dashed line), and both master regulators — HSF1 (1.40×) and SIRT1 (1.82×) — are themselves among the induced genes.

Table 2. Heat-shock-protein (chaperone) modules with the clearest roles in aging, the function each performs, and why each matters for the aging proteostasis network. Every module listed is represented among the 22 genes coordinately induced by Metadichol in human PBMCs (Figure 4).[51]

Chaperone module	Representative genes	Chaperone function	Relevance to aging
Master regulators	HSF1, HSF2, SIRT1	Transcriptional control of the heat-shock response; SIRT1 deacetylates and sustains HSF1 on chaperone promoters	Heat-shock response wanes with age; maintaining HSF1 activity extends lifespan and delays aggregation in model organisms
HSP70 machine	HSPA1A, HSPA8/HSC70, HSPA14, DNAJB1, BAG3	ATP-dependent refolding; HSC70 targets chaperone-mediated autophagy and BAG3 drives chaperone-assisted selective autophagy	Refolding capacity and selective-autophagy clearance both decline with age; their restoration improves proteostasis and healthspan
Disaggregase	HSPH1/HSP110 (with HSP70 and DNAJ)	Resolubilizes proteins already trapped in aggregates	Actively reverses the protein aggregates (e.g. tau, α-synuclein) central to neurodegeneration and cellular aging
Small HSPs (holdases)	HSPB1/HSP27, HSPB5/αB-crystallin	ATP-independent binding of unfolding proteins to block aggregation	Cytoprotective first line against aggregation; loss is linked to cataract, cardiomyopathy and neurodegeneration
HSP90 machine	HSP90AA1, HSP90AB1, CDC37, STIP1/HOP	Stabilizes client proteins (nuclear receptors, kinases) and buffers the proteome	Preserves signaling-protein stability; also restrains HSF1, so tuned modulation can amplify the stress response

Mitochondrial arm (UPRmt)	HSPD1/HSP60, HSPE1/HSP10, HSPA9/mortalin, TRAP1, DNAJA3	Import, folding and assembly of mitochondrial and respiratory-chain proteins	Drives the mitochondrial unfolded-protein response, among the best-validated longevity signals; mortalin also links to p53 and senescence
Endoplasmic-reticulum arm (UPR)	HSPA5/BiP, HSP90B1/GRP94/gp96	ER protein folding and the unfolded-protein response	ER proteostasis capacity falls with age, contributing to secretory and metabolic decline

Critically, the two master regulators were themselves induced — HSF1 by 1.40× and SIRT1 by 1.82× which supplies a transcriptional mechanism for the coordination: SIRT1 deacetylates HSF1 and prolongs its residence on the heat shock elements of chaperone-gene promoters, so a modest change in these two regulators is amplified across the network. [51] The dose–response was biphasic in the manner characteristic of Metadichol throughout this review: fourteen of the 22 genes peaked at 1 ng/mL and attenuated at 100 ng/mL, an inverted-U profile consistent with hormetic rather than proteotoxic activation, and the genes co-varied across five log-orders of dose rather than moving independently. Because Metadichol perturbs conventional housekeeping genes (Section 7), reference genes were validated by geNorm before analysis; HPRT1 and RPLP0 were the most stable pair and their geometric mean was used for normalization, while GAPDH was excluded.

This finding closes an important gap in the proteostasis hallmark. The autophagic and degradative arms described above clear damaged proteins; the chaperone network determines how many proteins fold correctly in the first place. Coordinate induction of both arms — chaperone capacity through HSF1/SIRT1, and clearance through SIRT1→FOXO and mTOR modulation — addresses loss of proteostasis more completely than agents acting on either arm alone. It also connects the hallmark to the rest of Metadichol’s profile: nuclear receptors are obligate clients of the HSP90–CDC37–STIP1 machine, ribosomal output is folded co-translationally by the HSPA14/HSPA8/DNAJB1 system (Section 4.3), Toll-like receptors are folded by gp96, and mitochondrial biogenesis requires matched matrix folding capacity (Section 4.2); these dependencies are summarized in Figure 4. These data are transcript-level; distinguishing directed Proteostasis regulation from a generalized hormetic stress response will require HSF1-dependence and chaperone-activity assays.[51]

2.5. Deregulated Nutrient Sensing

Nutrient-sensing pathways — principally insulin/IGF-1 signaling, mTOR, AMPK and the sirtuins — translate nutrient availability into growth and maintenance decisions. With age these pathways drift toward constitutive anabolic signaling, and their pharmacological restraint (caloric restriction, rapamycin, metformin) is among the most reproducible longevity interventions.

Metadichol’s Modulation: Metadichol demonstrates potent BCAT1 inhibition (3000× more potent than gabapentin), [27] directly modulating branched-chain amino acid metabolism linked to longevity. Lifelong restriction of dietary BCAAs has sex-specific benefits for frailty and lifespan in mice. [52,53] GPR120 agonism improves insulin sensitivity. mTOR pathway regulation, combined with comprehensive sirtuin activation, shifts metabolism toward the longevity-promoting state.

Beyond these sensors, the usable NAD⁺ pool is itself gated by CD38, the principal NAD⁺-consuming

NADase whose expression rises with age and is the dominant driver of the tissue-wide NAD⁺ decline that constrains sirtuin and PARP activity. [54,55] Because CD38, the sirtuins and the NAD⁺-salvage enzymes draw on a shared NAD⁺ pool, precursor supplementation (NMN/NR) is frequently insufficient when CD38 activity is high — the “leaking-bucket” problem of NAD⁺ repletion. [56,57] In human PBMCs, GAPDH-normalized qRT-PCR gives CD38 fold-changes of 0.45, 0.45, 0.52 and 0.30 across the 1 pg/mL to 100 ng/mL series (Figure 6). This apparent suppression should be interpreted with caution. The underlying quantification cycles show CD38 itself to be nearly unchanged from control through 1 ng/mL (C_T 28.84, 28.63, 28.35 and 28.94 respectively), rising by approximately 0.9 cycles only at 100 ng/mL (29.72), whereas the GAPDH reference falls from 22.59 in control to between 20.94 and 21.74 under treatment. The normalised ratio is therefore driven substantially by an increase in reference-gene signal rather than by a fall in CD38 transcript. Consistent with this, CD38 protein in Metadichol-treated PBMCs rises to 1.86× of control at 100 pg/mL by Western blot. We accordingly do not claim that Metadichol restrains the dominant NAD⁺ consumer, and the NAD⁺ argument advanced here does not depend on CD38. A better-supported route to the same endpoint runs through NAD⁺ synthesis rather than consumption: Metadichol induces the circadian transcription factors CLOCK and BMAL1, which directly drive transcription of NAMPT, the rate-limiting enzyme of the NAD⁺ salvage pathway, and NAMPT-derived NAD⁺ in turn activates SIRT1, which feeds back onto CLOCK–BMAL1 to close the loop. Metadichol’s induction of DDIT4/REDD1 with consequent mTORC1 restraint (Section 2.5.1) converges on the same NAMPT node through AMPK-type energy sensing. We propose, as a hypothesis rather than an established mechanism, that clock-driven NAMPT induction supports the NAD⁺ pool required by the sirtuins reported in Section 2.3 (Figure 5). Direct measurement of NAD⁺/NADH, re-normalization against a validated multi-gene reference, and a CD38 NADase activity assay are required to test this and are identified as priorities for future work.




Figure 5. The HSP / proteostasis network as an integrating hub. Arrows run from the chaperone network to each class of Metadichol-responsive gene that it folds, stabilizes or controls, with arrow color denoting the mediating chaperone module. Nuclear receptors, kinases, reprogramming and lineage transcription factors, Toll-like receptors, and the circadian and lymphoid programs discussed elsewhere in this review are, biochemically, clients of these modules. The single convergence arrow marks the net effect — restored proteostatic homeostasis — and the physiology and disease domains most plausibly impacted. The chaperone–target links summarize established chaperone biology and represent a proposed integrating mechanism; they are not, by themselves, Metadichol-specific causal proof.




Figure 6. CD38 transcript regulation by Metadichol in human PBMCs. CD38 is the dominant NAD⁺-consuming NADase, and its age-related rise constrains sirtuin and PARP activity.

2.5.1. The Integrated Stress Response (ATF4) as a Nutrient-Sensing and Longevity Node

A further nutrient-sensing axis that Metadichol engages is the integrated stress response (ISR), the eIF2α–ATF4 pathway that couples amino-acid, redox and energetic status to a defined transcriptional programme. [58] Companion work on Metadichol’s regulation of housekeeping and immune genes reports that ATF4 is induced ~4.06-fold in human PBMCs at 1 pg/mL and across six cancer lines, a cell-type-independent activation. [59] ATF4 is selectively translated through upstream open reading frames in its 5’-untranslated region when eIF2α is phosphorylated and bulk translation is restrained, [60] and it governs several hundred genes controlling amino-acid metabolism, autophagy, redox balance and apoptotic thresholds. [61] Its principal transcriptional target DDIT4/REDD1 inhibits mTORC1 through the TSC1/TSC2 complex, [62] an endogenous route to mTOR restraint that operates alongside Metadichol’s BCAT1 inhibition and, in parallel, a

squalene/FDFT1-dependent TSC pathway, [63] converging on the same catabolic, autophagy-permissive state described below (Section 2.10).

Two features make this axis relevant to aging rather than only to malignancy. First, ATF4 is a conserved longevity factor: genetic and pharmacological restraint of translation extends lifespan from *C. elegans* to mice, placing ISR activation within the same longevity space as caloric restriction. [64] Second, ATF4 facilitates induced-pluripotent-stem-cell generation, aligning the ISR with Metadichol’s induction of the Yamanaka reprogramming factors (Section 2.8). [65] By raising ATF4 at picogram concentrations, Metadichol adds a hormetic, mTOR-restraining stress-adaptive programme to its nutrient-sensing repertoire — reinforcing, rather than duplicating, the sirtuin, BCAT1 and NAD⁺-pool mechanisms already described.

Inset: CD38 fold-regulation across the dose series (qRT-PCR). Values are GAPDH-normalised. Because the GAPDH reference signal itself increases under treatment while raw CD38 C_γ is near-constant below 100 ng/mL, this figure should be read as a normalised transcript observation and not as evidence of reduced NADase activity or of a raised NAD⁺ pool. CD38 protein rises to 1.86× of control at 100 pg/mL by Western blot. NAD⁺/NADH was not measured in this work.




Figure 7. Metadichol: FOX-Sirtuin Regulatory Network. Direct regulation of FOX gene expression through sirtuin pathways. Metadichol activates all seven sirtuins: SIRT1, SIRT6, SIRT7 (nuclear), SIRT2 (cytoplasmic), and SIRT3, SIRT4, SIRT5 (mitochondrial). These sirtuins regulate multiple FOXO family members (FOXO1, FOXO3, FOXO4, FOXO6) and downstream processes including protein deacetylation, metabolic regulation, DNA repair, mitochondrial function, autophagy, and tumor suppression, culminating in enhanced longevity and health benefits.

2.6. Mitochondrial Dysfunction

Mitochondrial function deteriorates with age through mtDNA mutations, reduced biogenesis, impaired electron transport chain function, and defective quality control by mitophagy. [66,67] PGC-1 α serves as the master regulator of mitochondrial biogenesis. Age-associated loss of OPA1 in muscle impacts muscle mass, force, and systemic metabolism.[68]

Metadichol's Modulation: Metadichol upregulates PGC-1 α , the master regulator of mitochondrial biogenesis. [69] Mitochondrial sirtuins (SIRT3, SIRT4, SIRT5) are specifically activated, supporting mitochondrial protein function and metabolism. [3,18] Enhanced vitamin C synthesis provides antioxidant protection against mitochondrial oxidative damage. IDH1-mediated regulation of intracellular NADP⁺/NADPH ratio is supported through nuclear receptor activation.[70]

Metadichol's mitochondrial actions are complemented by restraint of hypoxia-inducible factor 1 α (HIF1 α), the transcriptional driver of aerobic glycolysis whose constitutive stabilisation reprograms metabolism away from oxidative phosphorylation. [71] Two of the sirtuins that Metadichol induces act directly on this node: SIRT1 deacetylates HIF1 α and promotes its destabilisation, [72] while SIRT6 represses HIF1 α -dependent glycolytic genes and re-establishes glucose homeostasis. [73] In companion work on non-malignant human PBMCs, Metadichol produced biphasic HIF1 α suppression (to ~0.45 $\times$ at 1 pg/mL) consistent with this SIRT1/SIRT6 action, whereas in oncogene-driven cells HIF1 α remained elevated — a context dependence that mirrors its protean, homeostatic mode of action. [59] For aging biology, tempering pseudo-hypoxic glycolytic signalling while supporting PGC-1 α -driven biogenesis favours the oxidative, low-ROS metabolic state associated with healthy mitochondrial function.[18]

Metadichol also supplies the matrix folding capacity that newly built mitochondria require. Alongside PGC-1 α -driven biogenesis, it co-induces the mitochondrial arm of the HSF1/SIRT1-anchored chaperone network — mortalin (HSPA9), the HSP60/HSP10 chaperonin (HSPD1/HSPE1), the mitochondrial HSP90 paralog TRAP1, and the J-protein DNAJA3 (the most strongly induced gene of the network at 4.00 $\times$) — so that biogenesis is matched by the folding, import and assembly capacity needed to build functional oxidative-phosphorylation complexes rather than misfolded, aggregation-prone subunits (Section 2.4).[51]

Beyond building and protecting individual mitochondria, Metadichol appears to interrupt the broader self-reinforcing circuit that links mitochondrial failure to cellular senescence — mitochondrial dysfunction-associated senescence (MiDAS). In this loop, a fall in membrane potential and electron-transport efficiency collapses the NAD⁺/NADH ratio, which drives ROS-mediated DNA damage and cytoplasmic chromatin fragments, activation of the cGAS-STING innate-immune sensor, a pro-inflammatory senescence-associated secretory phenotype (SASP), and impaired mitophagy that lets damaged mitochondria accumulate — each rotation amplifying the next. Metadichol's documented activities map onto every node of this cycle (Figure 8): mitochondrial biogenesis and OXPHOS-gene induction (PGC-1 α and the 13 mtDNA-encoded subunits) restore membrane potential and electron transport; induction of Sirtuins 1–7 together with clock-linked support of the NAD⁺ salvage pathway addresses the NAD⁺/NADH hub; Nrf2 and restored vitamin C biosynthesis lower oxidative DNA damage, while the HSF1/SIRT1 chaperone network and nucleoporin induction support proteostasis and nuclear-envelope integrity; control of LINE-1 retrotransposons and the alarmin HMGB1 limits the cytoplasmic-DNA triggers of cGAS-STING; NF- κ B-independent, TNF- α -lowering, NLRP3-suppressing action dampens the SASP; and SIRT1/PGC-1 α -driven turnover with restored macro autophagy renews mitochondrial quality control. By

relieving several drivers at once, Metadichol is positioned to break the self-amplifying rotation of the loop rather than to slow a single step of it.

Metadichol Breaks the Mitochondrial–Senescence Loop

One molecule intervening at every node of the MiDAS vicious cycle




Figure 8. Metadichol breaks the mitochondrial dysfunction–associated senescence (MiDAS) loop. The vicious cycle (red, clockwise) propagates from membrane-potential loss through NAD⁺ collapse, ROS/DNA damage, cGAS–STING activation, SASP and impaired mitophagy; Metadichol’s documented interventions (green spokes from the central hub) act at all seven nodes simultaneously.

2.7. Cellular Senescence

Cellular senescence is characterized by stable cell cycle arrest accompanied by the senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines. [74,75] p53 plays critical regulatory roles in cellular senescence. [13] p21 (CDKN1A) is a marker of aging and cellular senescence. [76,77] Naturally occurring p16Ink4a-positive cells shorten healthy lifespan.[78]

Metadichol’s Modulation: Klotho→TP53 modulation regulates senescence pathways. [26] Telomerase activation maintains telomere length, delaying replicative senescence. The comprehensive sirtuin network activation supports chromatin maintenance and cellular homeostasis. FOXO, KLF4, and SOX2 activation provides transcriptional regulation opposing senescence programs. [37,79] TLR2 controls the SASP, and Metadichol modulates all TLRs. [80] Mechanistically, p53 promotes the growth-arrest arm of senescence — largely through p21 (CDKN1A) — while simultaneously restraining the pro-inflammatory SASP via NF-κB inhibition, so Metadichol’s p53 induction is best read as a balanced, genome-protective tone rather than a simple senescence blockade.

2.7.1. Immune Clearance of Senescent Cells: The NKG2D Missing-Self Axis

Delaying senescence is only half of the problem; senescent and stress-marked cells must also be recognised and cleared by an immune system whose surveillance capacity itself declines with age. Metadichol supports this clearance while leaving the core antigen-presentation machinery intact. β2-microglobulin (B2M) is the invariant light chain required for assembly and surface display of all MHC class I molecules, [81] whose loss is a classic route by which damaged or transformed cells escape CD8+ T-cell recognition; [82] yet in companion housekeeping-gene work B2M remained essentially unchanged under Metadichol (~1.2-fold in human PBMCs, within the assay’s stable range), indicating that its near-constitutive expression is preserved rather than boosted — so MHC-I-dependent surveillance of antigen-bearing cells is maintained. [59] In parallel it engages the ‘missing-self’ pathway: the activating receptor NKG2D is upregulated (~8.59-fold), [83] and p53 — which Metadichol induces (Sections 2.1 and 11) — drives expression of the NKG2D ligands ULBP1/2 that flag stressed cells for natural-killer recognition. [84] Coupling preserved MHC-I surveillance of antigen-bearing cells with the enhanced NKG2D/ULBP signalling that flags MHC-low cells equips the immune system to remove the senescent and pre-malignant cells that accumulate with age, [85] complementing the intrinsic senescence-limiting mechanisms above.

2.8. Stem Cell Exhaustion

Stem cell populations decline in number and function with age, limiting tissue regeneration and repair capacity. [86] GDF11 is a circulating factor that reverses age-related cardiac hypertrophy. [18,87] In vivo partial reprogramming can ameliorate age-associated hallmarks.[88]

Metadichol’s Modulation: Metadichol induces Yamanaka reprogramming factors (Tables 3–6) with remarkable potency: OCT4 (↑19.6×), KLF4 (↑8×), and SOX2 (↑6.9×) in human fibroblasts and cancer cell lines. [65] This represents a potential non-viral approach to cellular rejuvenation. CD34 stem cell marker expression and GDF11 (rejuvenation factor) upregulation further support stem cell maintenance. [18,89] KLF transcription factors play critical roles in cellular reprogramming and longevity. [42,90] Because these reprogramming factors include the proto-oncogene c-MYC, their safety is supported by the accompanying lineage-fidelity data (Section 5.3), in which nine lineage-specific markers remained silent — indicating activation within existing chromatin accessibility rather than aberrant lineage switching.

Table 3. Q-RT-PCR results for Human Cardiac Fibroblast cells.

Metadichol concentration	NANOG	OCT 04 (POU5F1)	SOX2	KLF2	Klotho
	Fold Increase				

Control	1.00	1.00	1.00	1	1
1 pg	2.39	0.28	0.85	1.265	2.82
100 pg	5.86	10.36	10.21	2.468	10.13
1 ng	1.40	1.67	1.04	6.052	0.26
100 ng	0.22	0.96	2.55	14.81	0.19

Table 4. Q-RT-PCR results for A-549 cancer cells.

Metadichol concentration		Oct4 (POU5F1)	Klf4	Nanog	SOX2	Klotho
	Fold increase					
Control		1	1	1	1	1
1 pg		0.27	1.05	0.82	0.47	0.37
100 pg		0.92	0.44	0.82	0.80	0.60
1 ng		4.01	3.51	1.26	2.51	1.99
100 ng		1.25	1.58	0.81	0.73	0.83

Table 5. Q-RT-PCR results in COLO205 cancer cells.

Metadichol concentration		Oct4 (POU5F1)	Klf4	Nanog	SOX2	Klotho
	Fold increase					
Control		1	1	1	1	1
1 pg		0.41	2.55	1.74	1	1
100 pg		0.88	2.98	0.68	2.16	1.89
1 ng		1.79	13.17	0.41	2.21	1.22
100 ng		0.81	6.77	1.19	2.25	2.58

Table 6. Q-RT-PCR results following metadichol treatment in primary human cancer-associated fibroblasts (HCAF) triple-negative primary breast cancer (TNPBC).

Metadichol concentration	c-MYC	Oct4 (Pou5F1)	Klf4	SOX2	Klotho
	Fold increase				
Control	1	1	1	1	1
1 pg	3.36	4.56	3.36	0.57	2.13
100 pg	4.39	4.94	4.39	0.62	1.10

1 ng	4.04	19.63	8.07	2.45	0.64
100 ng	6.91	9.32	6.91	1.16	1.02

2.9. Altered Intercellular Communication

Aging disrupts intercellular communication through neurohormonal deregulation, inflammaging, and immunosenescence.[91,92] NF-κB signaling is the molecular culprit of inflammaging. [48,49] Toll-like receptors (TLRs) show dysregulation in human aging and immunosenescence.[38–40,93]

Metadichol’s Modulation: TNF-α downregulation reduces systemic inflammation. All TLRs (Toll-like receptors) modulation influences innate immune responses. [94] Circadian clock gene regulation (CLOCK, BMAL1, PER, CRY) restores temporal coordination of intercellular signaling. [95] Nuclear receptor network activation (49 receptors) comprehensively remodels cell communication. [96] VEGF signaling modulation counteracts age-related vascular insufficiency.[97]

2.10. Disabled Macroautophagy

Macroautophagy is the bulk lysosomal pathway that sequesters and degrades damaged organelles, protein aggregates, and surplus cytoplasm, sustaining cellular quality control. Its progressive failure with age has been formalised as a distinct hallmark in the expanded framework. [35,98] The pathway is held in check by mTOR and stimulated by the transcription factors TFEB and FOXO and the NAD+–sirtuin axis; declining autophagic flux drives proteostasis collapse and the accumulation of dysfunctional mitochondria.[98,99]

Metadichol’s Modulation: Metadichol promotes macroautophagy by converging on its principal positive regulators. Suppression of mTOR signalling — including through the DDIT4/REDD1 axis and potent BCAT1 inhibition — relieves the dominant brake on autophagy initiation. [27,100] Concurrent SIRT1→FOXO activation drives transcription of core autophagy genes (ATG family, LC3, BECN1) and chaperone-assisted selective autophagy through the FOXO3/BAG3 module. [18,46,47] As a vitamin D receptor ligand, Metadichol additionally engages VDR-dependent control of the autophagy effector ATG16L1. [101] The net result is restoration of the autophagic flux required to clear the molecular damage that accumulates with age.[98]

2.11. Chronic Inflammation (Inflammaging)

Chronic, low-grade sterile inflammation — termed inflammaging — is a pervasive feature of the aged organism, sustained by persistent NF-κB activation, the senescence-associated secretory phenotype (SASP), and circulating alarmins. It is a significant risk factor for morbidity and mortality, as most age-related diseases share an inflammatory pathogenesis.[35,102]

Metadichol’s Modulation: Metadichol opposes inflammaging at multiple nodes. It downregulates TNF-α and dampens NF-κB signalling, [48,49] while comprehensive sirtuin activation — notably SIRT1 and SIRT6, which deacetylate the NF-κB p65 (RelA) subunit and its target chromatin — imposes direct transcriptional restraint on the inflammatory programme. [18,103] Klotho induction (4–10×) suppresses TLR4-driven innate activation, [26,104] and modulation of the Toll-like receptor family rebalances innate immune tone. [105,106] Suppression of the alarmin HMGB1 together with restoration of the FOXP3/Treg axis further interrupts the self-amplifying sterile-inflammation loop that underlies immunosenescence.[85,107,108]

2.12. Dysbiosis

Dysbiosis — the age-associated erosion of gut microbial diversity and expansion of pro-inflammatory taxa — compromises the intestinal barrier, promotes systemic endotoxemia, and feeds inflammaging. Microbiome composition correlates with diet, health status, and frailty in older adults, making restoration of microbial and barrier homeostasis a recognised anti-aging target.[35,109]

Metadichol’s Modulation: Metadichol’s defining activity as a vitamin D receptor (VDR) ligand connects it directly to microbiome control. VDR signalling governs intestinal barrier integrity and the expression of antimicrobial peptides (cathelicidin, β -defensins) and the autophagy effector ATG16L1; loss of VDR function provokes dysbiosis, whereas VDR activation restores microbial balance and mucosal defence. [101,110] Consistent with this axis, Metadichol exhibits broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and parasites without cytotoxicity, [111,112] and its upregulation of FOXP3/Treg with suppression of TNF- α supports the gut immune tolerance that constrains pathobiont overgrowth. [85,108] Through VDR-mediated barrier and antimicrobial-peptide regulation, Metadichol is positioned to counteract the dysbiosis–inflammation cycle of aging.[110]

Metadichol acts as an inverse/protean agonist of the vitamin D receptor (VDR). [11] Unlike conventional VDR agonists such as 1,25-dihydroxyvitamin D3, inverse agonists stabilize inactive receptor conformations and can produce effects opposite to those of agonists. As a protean agonist, Metadichol exhibits agonist activity in the absence of constitutive receptor activity but inverse agonist activity when constitutive activity is present. [97] VDR signaling has profound effects on skeletal muscle and systemic metabolism. [113] This inverse-agonist mechanism has a concrete, testable readout: in monocyte lineages, constitutively active VDR suppresses vitamin D binding protein (VDBP), and Metadichol’s inverse agonism de-represses VDBP dose-dependently (7.1-fold in THP-1 and 8.4-fold in U937 cells at 100 ng/mL), reaching ~70% of the LPS-induced level without a cytokine storm.[114]

Metadichol increases the expression of all 49 human nuclear receptors — a finding reproduced across multiple human cell lines (up to seven) and confirmed at the protein level by Western blot (Section 5.3) (Figures 9 and 10). [96,115] Nuclear receptors serve critical roles in health and disease, integrating metabolic, inflammatory, and developmental signaling. [116–118] This includes thyroid hormone receptors (THRA, THRB), which regulate aging and homeostasis, [119–121] estrogen receptors (ESR1, ESR2) important for cardiovascular and metabolic health, [122,123] estrogen-related receptors (ESRRA, ESRRB, ESRRG) controlling energy homeostasis, [124,125] and REV-ERB/ROR receptors regulating circadian rhythms and metabolism.[126]




Figure 9. Nuclear receptors Sirtuins and Yamanaka factors in Anti-Aging pathways.




Figure 10. Nuclear receptor Network (reproduced from Ref 96).

The network shows extensive crosstalk among NRs, with highly connected central hubs including ESR1, AR, PPARG, PPARA, NR1H4 (FXR), RARA, and NR3C1 (GR).

Anti-Aging Implications

Metabolic Regulation: Simultaneous activation of PPAR family members (PPARA, PPARG, PPARD) would coordinate lipid metabolism, insulin sensitivity, and mitochondrial biogenesis—processes that decline with age and contribute to metabolic dysfunction.

Hormonal Homeostasis: Activation of steroid hormone receptors (ESR1/2, AR, NR3C1, PGR) could help maintain hormonal signaling that naturally attenuates during aging, potentially addressing sarcopenia, bone density loss, and cognitive decline.

Circadian and Inflammatory Control: ROR/REV-ERB family members (RORA, RORB, RORC, NR1D1/2) regulate circadian rhythms, which become dysregulated with age. The network also includes NRs that suppress chronic inflammation (e.g., GR, PPARs, LXRs).


Cellular Maintenance: Activation of receptors controlling autophagy, xenobiotic clearance (PXR/NR1I2, CAR/NR1I3), and bile acid homeostasis (FXR) supports cellular detoxification and quality control mechanisms.

Based on all the regulatory effects of Metadichol on various nuclear receptors pathways one can envision a mechanism of action (Figure 11) on how it regulates aging pathways at the downstream gene levels.

Metadichol & the Longevity Regulatory Network

A • Activation map

Metadichol and partners switch ON longevity pathways



B • Inhibition map

mTOR suppression (caloric-restriction mimetic) releases the longevity program




Figure 11. Metadichol: a master regulator.

Two complementary views of Metadichol’s regulatory reach are shown in Figure 11.

Panel A is a target-hierarchy map: from Metadichol, six functional categories resolve into their representative genes/factors and then into the cellular functions they restore (Figure 12).




Figure 12. Metadichol target-hierarchy map.

Panel B renders the same program as a mechanistic network, in which color-coded edges trace activation, promotion, modulation and suppression among the responsive genes — including the nuclear-pore (NUP), mitochondrial and heat-shock-protein (HSP) arms. Together they make explicit that the breadth described throughout this review is organized rather than diffuse, and that the same molecule reaches metabolic, longevity, immune, circadian and antioxidant program in parallel (Figure 13).




Figure 13. Integrated Metadichol regulatory network. Nodes are Metadichol-responsive genes/programs; edge color encodes activation (red), promotion/drives (green), modulation (grey) and indirect suppression (dashed), with the nuclear-pore (NUP), mitochondrial and heat-shock-protein (HSP) arms shown as dashed nodes.

Metadichol (top) acts through six functional categories — transcription factors, metabolic regulators, longevity factors, immune modulators, circadian controllers and antioxidant systems (purple) — each resolved into representative target genes/factors (orange: nuclear receptors [CAR/RXRA/PXR], the FOX, SOX and KLF families, Klotho, GDF11, PGC1A, mTOR, Sirtuins [SIRT1–7], BCAT1, TLRs 1–10 / MyD88, CLOCK/BMAL1/PER/CRY, TERT and vitamin C) that converge on the cellular functions restored in aging (magenta): cellular-senescence control, mitochondrial enhancement, growth regulation, metabolic control, inflammation resolution, circadian synchronization, telomere maintenance and oxidative protection. Legend: category / target-factor / function.

Table 7. Central Regulatory Hubs.

Hub	Role	Acts on
mTOR	Master nutrient sensor	Inhibits FOXO1, SIRT1, autophagy
SIRT1	NAD ⁺ sensor	Activates FOXO1, PGC-1 α , autophagy; modulates p53
FOXO1	Downstream effector	Promotes stress resistance, autophagy, mitochondrial function
Klotho	Anti-aging protein	Inhibits mTOR; activates SIRT1, FOXO1

Table 8. Regulatory Relationships.

Source	Effect	Target	Type
Metadichol	inhibits	mTOR (mimics caloric restriction)	Inhibitory
BCAT1 inhibition	inhibits	mTOR (mimics caloric restriction)	Inhibitory
Klotho	inhibits	mTOR	Inhibitory
mTOR	inhibits	FOXO1, SIRT1, autophagy	Inhibitory
SIRT1 / SIRT6	suppress	Inflammation, oxidative stress	Inhibitory
p53	inhibits	mTOR and TERT	Inhibitory
Metadichol	activates	Multiple longevity genes simultaneously	Activating
Klotho	activates	SIRT1, FOXO1	Activating
SIRT1	activates	FOXO1, PGC-1 α , autophagy; modulates p53	Activating
FOXO1	activates	Autophagy, oxidative-stress defense, PGC-1 α	Activating
PGC-1 α	enhances	Mitochondrial function (positive loop with SIRT1)	Activating
Vitamin C	supports	SIRT1 activity; reduces oxidative stress	Activating

Table 9. Cellular Outcomes.

Outcome	Type
Autophagy	Beneficial
Mitochondrial function	Beneficial
DNA repair	Beneficial
Telomere maintenance	Beneficial
Cellular senescence	Detrimental

Outcome	Type
Oxidative stress	Detrimental
Inflammation	Detrimental

Table 10. Critical Feedback Loops.

Loop	Function
PGC-1α ↔ SIRT1	Positive loop enhancing mitochondrial function and metabolic health
p53 ↔ DNA repair ↔ oxidative stress	Balances genome protection with cellular aging
mTOR ↔ autophagy	Key switch between growth and longevity modes

A comprehensive comparison of Metadichol with existing anti-aging interventions [32,127–147] reveals its unique multi-target advantage. (Tables 11 and 12) presents an overview comparison of primary mechanisms and target coverage.

Table 11. Overview comparison of anti-aging interventions. Green highlighting indicates advantageous properties; red indicates potential concerns.

Parameter	Metadichol	Resveratrol	Metformin	Rapamycin	NAD+ Boosters	Senolytics
Primary Mechanism	Multi-target systems modulation	SIRT1 activation	AMPK/mTOR	mTOR inhibition	NAD+ provision	Cell elimination
Number of Targets	13+ targets	1-2 targets	2-3 targets	1 primary	7 (indirect)	2-5 pathways
Safety Profile	GRAS status	Generally safe	Established	Immunosuppressive	Generally safe	Variable
Clinical Status	Early clinical	Mixed results	Extensive	Limited longevity	Promising	Early trials

Table 12. comparison of mechanism coverage across the hallmarks of aging.

Hallmark	Metadichol	Resveratrol	Metformin	Rapamycin	NAD+	Senolytics
Proteostasis	✓✓✓	○	✗	○	○	✗
Senescence	✓✓✓	○	✗	○	○	✓✓✓
Mitochondria	✓✓✓	○	✓✓	✓✓	✓✓	○
Inflammation	✓✓✓	○	○	✗	○	✓✓
Telomeres	✓✓✓	✗	✗	✗	○	✗
Circadian	✓✓✓	✗	✗	✗	○	✗

Hallmark	Metadichol	Resveratrol	Metformin	Rapamycin	NAD+	Senolytics
Metabolism	✓✓✓	•	✓✓✓	•	✓✓	•

Table 12. Mechanism coverage comparison. ✓✓✓ = Strong/Direct Effect; • = Moderate/Indirect Effect; ✕ = No/Minimal Effect. Green highlighting indicates strong effect.

The data reviewed here demonstrate that Metadichol possesses a remarkable capacity to modulate multiple hallmarks of aging simultaneously. This multi-target approach addresses a fundamental challenge in aging research: the interconnectedness of aging mechanisms means that targeting single pathways often produces limited benefits.[2,35]

Metadichol’s Unique Advantages

Unprecedented Target Coverage: Metadichol modulates 13+ molecular targets compared to 1-3 for conventional interventions. This comprehensive activation of sirtuins, nuclear receptors, and transcription factors creates synergistic effects addressing multiple hallmarks simultaneously.

Systems-Level Approach: Unlike single-target drugs, Metadichol addresses aging as an interconnected network. The activation of 49 nuclear receptors and over 2,300 genes — reproduced across cell lines and corroborated at the protein level — enables coordinated, context-dependent intervention across the nucleus, cytoplasm, and mitochondria.

Comparative Position

Comparative analysis reveals Metadichol’s unique position in the anti-aging landscape. While resveratrol primarily activates SIRT1, Metadichol activates all seven sirtuins. [18,29–31] While metformin focuses on AMPK/mTOR metabolic pathways, Metadichol additionally modulates telomerase, circadian rhythms, and stem cell factors. [5–7] While rapamycin’s mTOR inhibition carries immunosuppressive risks, Metadichol’s balanced modulation maintains immune function while activating longevity pathways.

Balanced Modulation: The protean agonist mechanism allows context-dependent responses, avoiding extreme pathway perturbation. This is particularly important for longevity interventions requiring chronic administration.

Safety Profile: GRAS (Generally Recognized as Safe) status, natural food-derived origin, and extensive toxicology studies showing no carcinogenicity over 18-24 months in rodent models [148,149] support long-term human use potential.

Non-Viral Reprogramming: The induction of Yamanaka factors without viral vectors (OCT4 ↑19.6×, KLF4 ↑8×, SOX2 ↑6.9×) offers potential for safe partial cellular reprogramming, a frontier approach in longevity research.[65,88]

The Biological Scale Framework

Beyond the nine hallmarks paradigm, the aging phenotype can be mapped across 12 hierarchical biological scales — from molecular DNA to whole-organism function. This framework, derived from the canonical aging phenotype model, provides a structural architecture for evaluating Metadichol’s interventional breadth. Metadichol uniquely engages all levels simultaneously.[2,12]

3.1. Genetic Scale: DNA Integrity Maintenance

At the foundational genetic scale, telomere shortening and genomic instability are the principal manifestations of aging. Metadichol addresses both through telomerase (TERT/TERC) upregulation and TP53 modulation. Critically, regulation of 31 nucleoporin (NUP) genes ensures the integrity of the nuclear pore complex, which governs nucleocytoplasmic transport of repair factors and transcription regulators.[96]

Key targets: Telomerase (TERT ↑16×), TP53, 31 NUP genes, 600+ DNA repair genes.[18,24,96]

3.2. Epigenetic Scale: Clock Resetting

Epigenetic drift — including altered DNA methylation patterns and histone modification disruption — drives the epigenetic clock, a quantifiable predictor of biological age. Metadichol activates all seven sirtuins (SIRT1-7, 3-15×) alongside the complete circadian clock gene network (CLOCK, BMAL1, PER1/2/3, CRY1/2), providing comprehensive epigenetic restoration unavailable from single-sirtuin activators such as resveratrol.[9,28,34]

Key targets: SIRT1-7 (all seven activated 3-15×), CLOCK, BMAL1, PER1/2/3, CRY1/2.[18,34,150]

3.3. Organelle Scale: Mitochondrial and Ribosomal Integrity

The organelle scale encompasses three primary aging manifestations: oxidative stress, mitochondrial dysfunction, and loss of proteostasis. Metadichol's approach is uniquely comprehensive: PGC1α upregulation (11.08× in PBMCs) drives mitochondrial biogenesis, while regulation of all 13 protein-coding mitochondrial genome genes (MT-ND1-6, MT-CO1-3, MT-ATP6/8, MT-CYB) provides direct support of the respiratory chain complexes I, III, IV, and V. Concurrently, regulation of all 79 ribosomal protein genes (RPL and RPS families) ensures translational fidelity, which undergoes stoichiometric disruption in aging cells.[16,17,69,85].

Key targets: PGC1α (↑11.08×), all 13 mitochondrial genome genes, all 79 ribosomal protein genes, Vitamin C, mTOR.[14,17,69,85]

3.4. Cellular Scale: Senescence Reversal and Stem Cell Renewal

Cellular senescence and stem cell exhaustion represent the functional culmination of upstream molecular damage. Metadichol addresses both simultaneously: Klotho and GDF11 suppress the senescence-associated secretory phenotype (SASP) while OCT4 (↑19.6×), KLF4 (↑8×), and SOX2 (↑6.9×) reactivate the Yamanaka reprogramming network, enabling partial cellular rejuvenation without viral vectors. Lineage-fidelity analysis confirms that these reprogramming factors are activated within existing chromatin accessibility windows — Metadichol does not force aberrant lineage switching.[2,3,18,65,85,88]

Key targets: OCT4 (↑19.6×), KLF4 (↑8×), SOX2 (↑6.9×), GDF11, Klotho, CD34.[26,65,87,115]

3.5. Tissue Scale: Anti-Fibrotic and Paracrine Restoration

At the tissue scale, fibrosis and disrupted intercellular communication are the dominant aging manifestations. Metadichol suppresses TNF-α and activates GPR120 (Free Fatty Acid Receptor 4), dampening NF-κB and the NLRP3 inflammasome — the principal drivers of fibrogenic signalling. Adiponectin upregulation restores metabolic paracrine communication, while regulation of the complete FOX and KLF gene families maintains cell identity and tissue compartmentalisation.[26–28,37,41,42,48,49,91]

Key targets: TNF-α ↓, GPR120, Adiponectin, All FOX genes (development & aging), All KLF genes (cell differentiation).[27,28,41,42]

3.6. Organ Scale: Neural, Muscular, and Pulmonary Preservation

Organ-level aging encompasses brain volume loss, sarcopenia, and increased lung compliance. SOX2-dependent neurogenesis supports hippocampal volume maintenance, FOXO3 — associated with human longevity in genome-wide association studies — promotes neural cell survival, and GDF11 has been demonstrated in parabiosis models to reverse age-related cardiac hypertrophy and skeletal muscle deterioration. PGC1α activation is the central mechanism opposing sarcopenic loss of skeletal muscle oxidative capacity.[6,20,23,30,69,87,151]

Key targets: SOX2, FOXO3, GDF11, PGC1α (↑11.08×), All SOX genes (neural development).[23,36,69,87,151]

Beyond preserving existing neurons, Metadichol appears able to reawaken neuronal identity programmes directly. In companion work it induced a panel of neuronal transcription factors —

ASCL1, NEUROG2 (NGN2), NR4A2/Nurr1, LMX1A and FOXA2 — even in non-neuronal human dermal fibroblasts. [59] NR4A2/Nurr1 and LMX1A are master regulators of dopaminergic-neuron specification and survival, making this observation directly relevant to Parkinson's disease, while ASCL1 and NGN2 are core factors in direct neuronal reprogramming (transdifferentiation) protocols. [152] Their induction in somatic cells parallels Metadichol's activation of the Yamanaka factors (Section 2.8) and of the FOX and SOX developmental networks, [41,151] suggesting a unified capacity to open regenerative transcriptional programmes within accessible chromatin rather than to force ectopic fates (Section 5.3). Together with regulation of the 31 nucleoporin genes that maintain nuclear-pore integrity — whose failure underlies TDP-43 mislocalisation in ALS and nucleoporin loss in Parkinson's and Alzheimer's disease (Section 4.1) — this positions Metadichol's organ-scale neural action as both protective and potentially regenerative.[96]

3.7. System Scale: Metabolic and Immune Restoration

At the systemic scale, Metadichol addresses four concurrent age-related pathologies. For insulin resistance, PPAR γ upregulation (24.25 $\times$ in treated PBMCs) exceeds the effect magnitude of thiazolidinedione pharmacotherapy without associated adverse effects. For arteriosclerosis, ACE regulation, adiponectin upregulation, and TNF- α suppression address vascular stiffening at multiple molecular nodes. For immunosenescence, regulation of all TLRs, 20 NK cell factors, 35 master regulatory genes (including FOXP3 $\uparrow$ 1.87 $\times$, the 2025 Nobel Prize target), and HMGB1 suppression comprehensively restores innate and adaptive immune competence.[21,85,105–107,153]

Key targets: PPAR γ ($\uparrow$ 24.25 $\times$), ACE, All TLRs, 20 NK Cell Factors, FOXP3 ($\uparrow$ 1.87 $\times$), 35 Master Regulators, HMGB1 $\downarrow$, TMRSS2.[85,96,105,106,154]

3.8. Functional Scale: The Longevity Axis

The functional scale — gait, cognition, and longevity — represents the integrated output of all upstream corrections. Metadichol simultaneously activates the three best-validated longevity pathways in geroscience: Telomerase (telomere maintenance), SIRT1-7 (epigenetic and metabolic longevity), and Klotho (anti-aging systemic protein). The simultaneous activation of all three pathways by a single molecule represents a mechanistic convergence without precedent in the pharmacological anti-aging literature.[18,24,26,85]

Key targets: Telomerase + SIRT1-7 + Klotho (three-pathway longevity convergence), 49 nuclear receptors.[18,24,26]

4. Structural and Organelle Gene Regulation: NUP, Mitochondrial, and Ribosomal Genes

A critical and underappreciated dimension of Metadichol's anti-aging activity is its comprehensive regulation of structural gene families essential for cellular architecture and energy metabolism. This compartment-level, coordinated regulation is summarized in Figure 14.




Figure 14. Metadichol coordinately regulates the cell's core structural and regulatory machinery.

From a single upstream event — VDR inverse/protean agonism — Metadichol tunes six systems in their native compartments: all 49 nuclear receptors and the nuclear sirtuins (SIRT1/6/7) within the nucleus; the 31-gene nuclear-pore complex (NUP) in the nuclear envelope; all 79 ribosomal-protein genes on the endoplasmic reticulum; mitochondrial biogenesis (PGC-1α ↑11x, the 13 mtDNA-encoded genes, SIRT3/4/5 and the mitoralin/HSP60 folding arm); the 22-gene HSF1/SIRT1 chaperone network; and Sirtuins 1–7 (↑3–15x) across nuclear, cytoplasmic and mitochondrial compartments, with the NAD⁺ pool addressed through clock-linked salvage-pathway support. The coordinated output maps onto genomic stability, telomere maintenance, epigenetic homeostasis, restored

proteostasis, mitochondrial energetics, reduced senescence and inflammation, and stem-cell renewal — converging on healthy aging and longevity.

4.1. Nuclear Pore Complex: 31 Nucleoporin Genes

The nuclear pore complex (NPC) — comprising ~30 distinct nucleoporin proteins — governs all nucleocytoplasmic transport, including the import of transcription factors and DNA repair proteins and the export of mRNA and ribosomal subunits. NPC integrity declines with age, contributing to chromatin leakage, epigenetic dysregulation, and impaired DNA damage response. Metadichol regulates 31 NUP genes, providing comprehensive support of the transport machinery essential for all gene regulatory cascades it initiates.[85,96]

Clinical significance: NPC dysfunction is implicated in neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS. Restoration of nucleoporin expression may contribute to Metadichol’s neuroprotective effects.[96]

4.2. Mitochondrial Genome: All 13 Protein-Coding Genes

The human mitochondrial genome encodes exactly 13 proteins, all of which are essential subunits of the oxidative phosphorylation complexes: MT-ND1 through MT-ND6 (NADH dehydrogenase, Complex I), MT-CO1 through MT-CO3 (cytochrome c oxidase, Complex IV), MT-ATP6 and MT-ATP8 (ATP synthase, Complex V), and MT-CYB (cytochrome bc1, Complex III). Age-associated accumulation of mtDNA mutations progressively impairs these components, reducing ATP yield and increasing electron leak and ROS production. Metadichol regulates all 13 of these genes, providing the most comprehensive mitochondrial genome-level intervention of any reported compound.[13,14,66,69,85]

This dual nuclear/mitochondrial coordination — PGC1 α -driven biogenesis in the nucleus plus direct mtDNA gene regulation — is essential for maintaining mitochondrial membrane potential and preventing the bioenergetic decline central to aging.[14,69]

Direct mtDNA gene regulation is only productive if the encoded subunits fold and assemble correctly within the matrix. Metadichol meets this demand by co-inducing the mitochondrial chaperone arm (mortalin/HSPA9, HSPD1/HSPE1, TRAP1 and DNAJA3; Section 2.4), coupling expression of the 13 protein-coding genes to the Proteostasis capacity required to assemble them into stable respiratory complexes.[51]

Unique distinction: No existing anti-aging pharmacological agent targets the complete mitochondrial genome. This represents a novel mechanistic dimension of Metadichol’s anti-aging profile.

4.3. Ribosomal Protein Genes: All 79 RPL/RPS Family Members

Ribosome biogenesis requires the coordinated expression of 79 ribosomal protein genes (RPL1-40 and RPS2-30 families). Age-associated ribosomal protein stoichiometric imbalance — well-documented in yeast aging models and increasingly recognized in mammalian systems — impairs translational fidelity, promotes misfolded protein accumulation, and contributes to proteostasis collapse. Metadichol’s regulation of all 79 ribosomal protein genes ensures the integrity of the translational apparatus itself, providing an upstream solution to the proteostasis crisis of aging distinct from mTOR-focused approaches.[5,16,17]

Integration with mTOR: Metadichol modulates mTOR (ribosome assembly regulation) and the 79 ribosomal protein genes (translational fidelity). This dual approach addresses both the quantity and quality of protein synthesis in aging cells.

The significance of regulating all 79 ribosomal-protein genes is clarified by the biology of ribosome biogenesis in growth and aging. Ribosomal-protein mRNAs carry 5’ terminal oligopyrimidine (5’TOP) motifs that render their translation strictly mTOR-dependent, [155,156] coupling ribosome production to anabolic signalling; unchecked, this yields the velocity-maximising,

error-prone translome characteristic of aged and transformed cells. [157] By upregulating the ribosomal-protein complement while simultaneously restraining mTORC1 (via DDIT4/REDD1 and BCAT1 inhibition; Sections 2.5 and 2.10), Metadichol favours ribosome renewal under fidelity-enforcing rather than growth-maximising conditions — the translational signature of caloric restriction, itself a canonical longevity intervention. [64] This is reinforced by SIRT7, the nucleolar sirtuin among the seven Metadichol induces, which governs RNA-polymerase-I transcription at ribosomal-DNA loci and enforces the rRNA-to-protein stoichiometry required for accurate assembly.[158,159]

Ribosome-biogenesis surveillance also links this hallmark back to genomic stability. When assembly is perturbed, free RPL5 and RPL11 bind and inhibit MDM2, stabilising p53 through the ribosomal-stress checkpoint, [160,161] providing a second, assembly-coupled route to the p53 induction described in Sections 2.1 and 11. The clinical corollary is that ribosomal-protein dysregulation causes defined ribosomopathies — Diamond–Blackfan anaemia (RPS19, RPL5, RPL11), [162] del(5q) myelodysplastic syndrome (RPS14 haploinsufficiency), [163] and relapsed chronic lymphocytic leukaemia (somatic RPS15 mutations) [164] — contexts in which coordinate restoration of the ribosomal-protein network is mechanistically attractive. Full quantitative documentation of the 79-gene response appears in the companion analysis.[59]

5. T, B, and NK Cell Immunity Through Master Regulator Gene Networks

A landmark study profiled 36 master regulator genes across PBMCs (13 immune markers) and NHDF fibroblasts (23 stromal markers) after Metadichol treatment at four doses (1 pg/mL, 100 pg/mL, 1 ng/mL, 100 ng/mL), with Q-RT-PCR profiling and Western blot validation. This study was anchored to the 2025 Nobel Prize in Physiology or Medicine, which recognised the discovery of regulatory T cells and the FOXP3 master regulator.[85,108]

5.1. Headline Upregulation Results

The study identified four headline findings of particular biological significance:

- PPAR γ : 24.25 $\times$ upregulation (metabolic master regulator; exceeds thiazolidinedione effect without adverse metabolic consequences)[85]
- PGC1 α : 11.08 $\times$ upregulation (mitochondrial biogenesis master coactivator; mRNA vs 1.21 $\times$ protein, controlled by miR-696/miR-23a)[85]
- FOXP3: 1.87 $\times$ upregulation (Treg master regulator; Nobel Prize 2025 target; cross-confirmed in fibroblasts 1.58 $\times$ — same molecule, two systems)[85,108]
- CD4/CD8: 2.0–2.4 $\times$ upregulation (T-cell effector arm; supports adaptive immune competence)[85]

5.2. Three Convergent Themes Across Lineages

Analysis of gene expression across T cells, B cells, and NK cells revealed three convergent themes absent from single-target interventions:[85]

Theme 1 — Metabolic Master Regulators as Universal Enhancers: PPAR γ , PGC1 α , and HIF support effector and memory T-cell function, B-cell antibody production, and NK-cell sustained cytotoxicity in hypoxic environments alike. Metabolic programming, not immune-specific signalling, is the shared currency of immune enhancement.

Theme 2 — Effector vs. Regulatory Antagonism Mirrors Across Lineages: BLIMP1 drives plasma-cell differentiation while inhibiting memory B-cell formation, directly paralleling the Treg/Teff balance shift in T cells. This suggests a unified metabolic-regulatory framework across all three lymphocyte lineages.[85]

Theme 3 — Co-stimulatory Tone Uniformly Dampened: CD27, CD80, and CD86 downregulation reduces co-stimulation-dependent activation across all three lineages, substituting

metabolic resilience for activation-dependent signalling — a shift from inflammatory to homeostatic immune programming.[85]

5.3. RT-PCR / Western Blot Concordance and Lineage Safety

Cross-platform validation demonstrated high concordance:

- PBMC markers: 11/13 directional agreement between mRNA (Q-RT-PCR) and protein (Western blot)[85]
- Fibroblast markers: 9/10 directional agreement[85]
- Informative discordances: CD80/CD86 (mRNA-suppressed but protein-stabilised, reflecting post-transcriptional buffering); PGC1 α (11.08 $\times$ mRNA vs 1.21 $\times$ protein, controlled by miR-696/miR-23a)

Lineage faithfulness analysis confirmed that nine lineage-specific markers (TAL1, PU.1, BLIMP1, P63, MTF, GCM1, FOXJ1, SIM1, PROX1) remained absent in fibroblasts at every concentration, demonstrating that Metadichol activates master regulators within existing chromatin accessibility — it does not force aberrant lineage switching. [85] *Safety implication: Metadichol engages the molecular machinery of immune rejuvenation without disrupting the fundamental boundaries of cell identity that protect against neoplastic transformation.*

5.4. CD28 Co-Stimulation and the Reversal of T-Cell Immunosenescence

Within the T-cell arm of this immune program, one costimulatory receptor merits special attention because its loss is the single most reproducible molecular marker of human immune aging: CD28. In newborns nearly every naïve T cell expresses CD28, but by the eighth–ninth decade large populations—especially CD8⁺ cytotoxic cells—have silenced it, and the frequency of these CD28-null cells predicts poor vaccine responses, chronic inflammation, and adverse clinical outcomes. [165,166] CD28 delivers “Signal 2” of T-cell activation by engaging CD80/CD86 on antigen-presenting cells; without it, an antigen-experienced cell is driven into anergy rather than activation. [167] Crucially, CD28 silencing is an actively repressed, epigenetically encoded program—not a gene deletion—and is therefore, in principle, reversible. [168]

In primary human PBMCs, Metadichol re-induced CD28 at both the protein (up to 1.23-fold) and transcript (up to 1.43-fold) levels. This occurred within a broad, coordinated shift opposite to the immunosenescent signature: the costimulatory and memory markers CD27 (1.64 $\times$), CD80 and CD86 (1.48 $\times$); the T-cell lineage markers CD4 (2.72 $\times$) and CD8; and the natural-killer maturation axis CD122/IL-2R β (1.96 $\times$), CD336/NKp46 (2.41 $\times$), CD56, EOMES (1.57 $\times$) and TBET (1.47 $\times$) were all upregulated, while the inhibitory receptor NKG2A (0.65 $\times$) and the naïve/senescence-associated markers CD45RA (0.51 $\times$) and CD10 (0.53 $\times$) were suppressed (Figure 15). The simultaneous reinforcement of the CD28 receptor, its B7 ligands and its adhesion partners (CD2/CD58) describes strengthening of the entire costimulatory module rather than modulation of a single node.




Figure 15. CD28 at the hub of the costimulatory network and its role in immune aging. The immune synapse pairs antigen recognition (MHC–peptide↔TCR·CD3, Signal 1) with CD28 engagement of the shared B7 dock (CD80/CD86, Signal 2, “GO”), which is also bound by the inhibitory checkpoint CTLA-4 (“STOP”); CD2↔CD58/LFA-3 stabilizes the contact. With CD28 maintained the costimulatory and NK-maturation partners are upregulated; with CD28 silenced by chronic antigen, CMV and TNF-α the compartment drifts to a CD28-null, CD45RA+ senescent state. Metadichol re-induces CD28 and its partners while lowering CD45RA, CD10 and NKG2A (fold-changes from Metadichol-treated human PBMCs).

This pattern is significant for aging biology because it simultaneously strengthens costimulation, expands the effector compartment, and matures the NK-like cytotoxic program that clears senescent and malignant cells—directly countering the altered-intercellular-communication and cellular-senescence hallmarks as they manifest in the immune system. Notably, Metadichol produces modest, graded, hormetic changes across a four-log concentration range and modulates the entire costimulatory ecosystem, in contrast to the dangerous, supraphysiological forcing of a CD28 superagonist. By re-inducing the very signal that immunosenescence erases, Metadichol reframes immune aging as a modifiable dial rather than a fixed verdict.

6. IL-15 and NK Cell Maturation: CD122/IL-15 Signalling

NK cell dysfunction is a hallmark of immunosenescence, with NK cell cytotoxicity declining significantly with age. A dedicated investigation of Metadichol’s effects on NK cell maturation identified a novel mechanism: activation of the CD122/IL-15 signalling axis through NF-κB-independent pathways. [92,153,169]

IL-15, signalling through the IL-15Rα/CD122/CD132 heterotrimeric complex, is the primary cytokine driving NK cell development, homeostasis, and effector function. Unlike the well-characterised NF-κB-dependent pathway of IL-15 action, Metadichol activates an NF-κB-independent route, circumventing the pro-inflammatory sequelae of direct NF-κB activation — a critical distinction for a compound intended for chronic anti-aging use. [153,169]

The 20 NK cell factors regulated by Metadichol include components of the CD122 receptor complex, downstream JAK-STAT signalling elements, and NK cell cytolytic machinery (GzmB, IFNγ). This comprehensive NK cell support has direct relevance to immunosenescence, cancer immunosurveillance, and viral defence in aged individuals. [85,153]

Clinical significance: IL-15 deficiency contributes to the age-associated decline in NK cytotoxicity that increases cancer susceptibility and infectious disease severity. Metadichol’s NF-κB-independent IL-15 pathway activation represents a safe approach to NK cell rejuvenation. [92]

7. Housekeeping Gene Expression in Metadichol-Treated PBMCs

A critical question for any multi-target agent is whether it perturbs essential cellular infrastructure. Analysis of housekeeping gene expression in Metadichol-treated PBMCs addressed this directly, examining 19 genes classified as ‘undruggable’ due to their roles in fundamental cellular processes. [59]

The 19 housekeeping genes examined represent ubiquitous essential functions including ribosomal protein production, proteasomal degradation, cytoskeletal integrity, DNA replication fidelity, and mRNA splicing — functions that must be maintained for cellular viability. The finding that Metadichol can modulate expression in this class of genes while maintaining cellular viability across multiple cell types (PBMCs, fibroblasts, cardiac cells, cancer lines) demonstrates a fundamentally different mechanism from cytotoxic interventions. [59]

Importantly, the dose-dependent expression patterns of these genes — consistent with Metadichol’s characteristic picomolar-to-nanomolar activity range — suggest that even targets historically considered intractable to pharmacological modulation may be accessible through nuclear receptor-mediated transcriptional reprogramming. [59]

From undruggable to therapeutic:

Metadichol’s engagement of housekeeping gene networks positions it as a new class of systems-level modulator capable of restoring fundamental cellular functions that decline with age.

To test whether this behavior generalizes beyond primary immune cells, the same 19-gene panel and dose range were applied to six human cancer lines spanning distinct tissues — lung (A549), hypopharyngeal (FaDu), colorectal (HCT116), cervical (HeLa), hepatocellular (HepG2) and glioblastoma (U87MG) (Table 13). [59] Three features of the result bear directly on aging biology. First, the response is context-set rather than fixed: HIF1A, which Metadichol biphasically suppressed in resting PBMCs (to ≈0.45×, consistent with SIRT1-mediated destabilization when mTOR drive is low), was instead induced in every transformed line (mean ≈3.1×, up to 4.69× in HCT116), because the tumor’s constitutive PI3K/mTOR and pseudohypoxic Warburg background shifts the mTOR–SIRT1 balance that the compound tunes. This state-dependent, bidirectional output — the same nuclear-receptor input landing on the stabilizing or destabilizing arm according to a cell’s baseline — is the property that allows a single agent to act as a homeostatic set-point corrector rather than a unidirectional driver, and it underlies the expectation that Metadichol nudges stressed or senescent cells without overriding the tuned state of healthy ones. Second, the proteostatic reinforcement central to this review scales with proteotoxic burden: ATF4-driven chaperone induction was

markedly larger in the cancer lines than in PBMCs (HSPA5 up to 3.83× in HCT116; HSPA9 up to 3.61× in HepG2), consistent with the integrated stress response engaging most strongly precisely where unfolded-protein load is highest — the same logic that predicts benefit in the proteostasis decline of aged and stressed cells. Third, the FOXO/SIRT1-linked tumor-suppressor PTPRO, frequently silenced by promoter hypermethylation, was re-expressed across all six lines regardless of tissue of origin, reinforcing the genome-guardian axis that links Metadichol’s cancer-resistance and longevity effects (Section 11). Throughout, the constitutive machinery and the antigen-presentation gene B2M remained near baseline in both compartments, indicating that modulation is confined to adaptive stress and tumor-suppressor nodes rather than to essential infrastructure — the selectivity a geroprotective agent requires.

Table 13. Aging-relevant housekeeping genes — peak Metadichol response in PBMCs versus six cancer cell lines. Peak fold-change relative to control ($2^{-\Delta\Delta Cq}$, GAPDH-normalized). PBMC values are the peak across the 0.1 pg/mL–100 ng/mL series; cancer values are the mean and range across A549, FaDu, HCT116, HeLa, HepG2 and U87MG. ATF4 and the chaperones reinforce proteostasis, PTPRO restores a tumour-suppressor node, and HIF1A illustrates the context-set reversal (suppressed in resting immune cells, induced on a tumour background).

Gene	PBMC peak (direction)	Cancer mean (range)	Aging-relevant readout
ATF4	4.06× (up)	3.05× (2.16–3.56×)	Conserved integrated-stress-response activation in normal and transformed cells
PTPRO	6.02× (up)	2.75× (1.63–3.51×)	FOXO/SIRT1-linked tumour-suppressor re-expression; genome-guardian axis
HSPA5	1.33× (up)	2.66× (1.47–3.83×)	ER unfolded-protein-response chaperone (BiP/GRP78); scales with proteotoxic load
HSPA9	1.31× (up)	2.71× (2.19–3.61×)	Mitochondrial chaperone (mortalin); proteostatic reinforcement
HIF1A	0.45× (down)	3.09× (2.29–4.69×)	Direction reversed — context-set, bidirectional output

8. LINE1, HMGB1, and USAG1: Systems-Level Immune Enhancement

A systems-level paradigm study identified three additional regulatory targets of Metadichol with significant implications for aging biology:

8.1. LINE1 Retrotransposon Control

LINE-1 (Long Interspersed Nuclear Element 1) retrotransposons constitute approximately 17% of the human genome and are normally silenced by epigenetic mechanisms. With aging, LINE-1 elements become progressively demethylated and transcriptionally active, producing reverse transcriptase-mediated insertional mutagenesis, cDNA-triggered innate immune activation (cGAS-STING pathway), and genomic instability. Metadichol’s regulation of LINE-1 expression — likely mediated through sirtuin-dependent chromatin maintenance and nuclear receptor-driven transcriptional silencing — represents a previously unreported mechanism of genomic stability preservation with direct relevance to the aging epigenome. [18,107]

8.2. HMGB1 Alarmin Suppression

High Mobility Group Box 1 (HMGB1) is a nuclear chromatin-binding protein that is released extracellularly by senescent and necrotic cells, functioning as a danger-associated molecular pattern (DAMP) that activates TLR2, TLR4, and RAGE receptors. HMGB1 is a principal driver of the sterile inflammation underlying both the SASP and immunosenescence, and serum HMGB1 levels correlate with biological age and frailty. Metadichol suppression of HMGB1 thus provides a molecular brake on the feed-forward inflammatory cycle that accelerates aging at the cellular, tissue, and systemic levels simultaneously. [45,107]

8.3. USAG1 and Regenerative Potential

USAG1 (Uterine Sensitization-Associated Gene 1, also known as Sostdc1) is a BMP antagonist originally identified for its role in tooth development. Recent research has identified USAG1 inhibition as a strategy for tooth regeneration in adults and for regulation of kidney and bone metabolism. Metadichol’s regulation of USAG1 connects its multi-target profile to regenerative biology beyond the classical aging pathways, suggesting applications in tissue regeneration that merit dedicated investigation (Figure 16). [107]

Section 8 — LINE-1, HMGB1 & USAG1: a "controlled-burn" systems-level programme

Three under-appreciated Metadichol targets that convert genomic-instability and alarmin signals into immune enhancement and regeneration.




Figure 16. LINE-1, HMGB1 and USAG1 — a “controlled-burn” systems-level program. Metadichol engages three under-appreciated targets: it holds LINE-1 retrotransposons under SIRT6-dependent chromatin control (preserving genomic stability while permitting a controlled cGAS–STING / Type-I-interferon “viral-mimicry” pulse that raises immunogenicity); it suppresses the alarmin HMGB1 (a DAMP acting through TLR2/TLR4/RAGE), braking the feed-forward sterile-inflammation loop of the SASP and immunosenescence; and it regulates USAG1/SOSTDC1, a dual BMP/Wnt antagonist, linking the profile to tissue regeneration. The net effect is to re-purpose genomic-damage signals rather than merely suppress them — enhancing immune surveillance, reducing inflammaging and supporting regeneration.

9. The Inferred Hierarchical Regulatory Cascade

Co-regulation pattern analysis across all Metadichol studies, combined with existing knowledge of nuclear receptor signalling hierarchies, supports an inferred regulatory cascade through which a single VDR inverse agonist interaction propagates to modulate over 2,300 genes across all biological scales (Figure 17):




Figure 17. The inferred hierarchical regulatory cascade. A single VDR inverse/protean-agonist interaction propagates through five tiers — (1) all 49 nuclear receptors (PPAR γ $\uparrow$ 24.25 $\times$); (2) the seven sirtuins (SIRT1–7 $\uparrow$ 3–15 $\times$); (3) Klotho ($\uparrow$ 4–10 $\times$), which suppresses IGF-1/insulin and TLR4 signalling and feeds back to activate SIRT1/FOXO1; (4) the TLR, FOX and KLF networks governing innate immunity, development/longevity and cell fate; and (5) the circadian network (CLOCK, BMAL1, PER1/2/3, CRY1/2) — culminating in modulation of >2,300 genes across all biological scales. The cascade is inferred from co-regulation patterns; direct causal ordering (receptor knockdown / time-course) remains for future validation.

Level 1 — Nuclear Receptors: VDR inverse agonism initiates a cascade of nuclear receptor co-activation, ultimately engaging all 49 known nuclear receptors. PPAR γ (24.25 $\times$) represents the most dramatically upregulated primary target, with downstream effects on metabolic, immune, and mitochondrial gene networks. [21,85,96,113,114,154]

Level 2 — Sirtuins: Nuclear receptor activation drives NAD⁺-sirtuin pathway engagement. All seven sirtuins (SIRT1-7) are upregulated 3-15 $\times$, providing comprehensive NAD⁺-dependent deacetylase activity across nuclear (SIRT1, SIRT6, SIRT7), cytoplasmic (SIRT2), and mitochondrial (SIRT3, SIRT4, SIRT5) compartments. [18]

Level 3 — Klotho: Sirtuin-mediated chromatin remodeling and nuclear receptor activation converge on Klotho upregulation (4-10 $\times$). Klotho suppresses IGF-1/insulin signaling, dampens TLR4 activity (anti-aging), and activates SIRT1 and FOXO1 in a positive feedback loop that reinforces longevity programming. [8,9,26]

Level 4 — TLR/FOX/KLF Networks: Klotho-mediated TLR dampening and FOXO activation, combined with direct nuclear receptor regulation, drive comprehensive expression of TLR families (innate immune restoration), FOX transcription factors (development, aging, and longevity), and KLF factors (cell fate, metabolism, and stem cell maintenance). [37,41,42,90,94,105,106,170]

Level 5 — Circadian Network: The final tier of the cascade engages circadian clock genes (CLOCK, BMAL1, PER1/2/3, CRY1/2), restoring the temporal coordination of gene expression that

becomes progressively dysregulated with age. Circadian disruption is both a cause and consequence of aging, and its restoration at the transcriptional level has systemic implications for metabolism, immune function, and DNA repair. [12,95,96,150]

Important caveat: This hierarchical cascade is inferred from co-regulation patterns and prior Metadichol literature. Direct causal validation through receptor knockout experiments has not been performed in the current experimental systems and constitutes a priority for future mechanistic studies. [85,113]

10. Vitamin C Biosynthesis and Antioxidant Gene Networks

A well-documented activity of Metadichol is an increase in Vitamin C availability across species. In animals that retain a functional GULO gene (L-gulonolactone oxidase) — for example mouse cells and adipocytes — Metadichol upregulates GULO and related biosynthetic genes, enhancing de novo Vitamin C synthesis. [171] Humans, other primates and guinea pigs carry a pseudogenised GULO gene, so de novo synthesis cannot be reconstituted in humans; nonetheless, increased Vitamin C has been documented in humans in open-label studies, an effect attributed to regeneration of reduced ascorbate from dehydroascorbate (recycling) together with enhanced retention through Metadichol-induced antioxidant gene networks. [19,172–174]

Studies across multiple mammalian species showed dose-dependent upregulation of Vitamin C synthesis/recycling gene expression in Metadichol-treated cells, with in vivo evidence — including open-label human studies — of increased Vitamin C in treated subjects. [173,174] In GULO-competent species this includes reactivation of biosynthetic (GULO) gene expression and de novo synthesis; [171] in humans, where GULO is pseudogenised, the increase reflects nuclear receptor-mediated induction of the ascorbate-recycling network (reduction of dehydroascorbate to ascorbate) rather than reconstitution of the defunct de novo pathway. [19,113,172]

This finding has direct anti-aging implications: Vitamin C is a critical cofactor for collagen synthesis, an electron donor for antioxidant recycling, and a cofactor for ten-eleven translocation (TET) DNA demethylases involved in epigenetic-clock maintenance. Metadichol-induced enhancement of Vitamin C availability — de novo in GULO-competent species and via recycling in humans — thus contributes simultaneously to genomic stability, epigenetic homeostasis, and extracellular-matrix integrity. [9,172]

11. Peto's Paradox and the Tp53 Connection: Metadichol Phenocopies the Elephants Cancer Resistance

A striking illustration of how aging and cancer resistance intersect is Peto's paradox. Cancer arises from mutations that accumulate as cells divide, so large, long-lived animals—which have vastly more cells and more cell divisions over a lifetime—should suffer proportionally more cancer. They do not. Elephants carry roughly 100 times more cells than humans and live 60–70 years, yet fewer than 5% die of cancer, compared with 17–25% of humans. The resolution centers on the tumor-suppressor gene TP53, the “guardian of the genome,” whose p53 protein detects DNA damage, arrests the cell cycle, directs repair, and triggers apoptosis when damage is beyond repair. Humans carry a single functional TP53 gene (two alleles); elephants have amassed approximately 20 copies, including multiple functional retrogenes, together with a TP53-activated “zombie” LIF6 gene, giving them a markedly amplified DNA-damage response. [175–177]

Metadichol offers a pharmacological analogue in human cells: rather than adding gene copies, it increases p53 expression. In normal human dermal fibroblasts, Metadichol induced p53 in a dose-dependent manner, reaching 4.11-fold at 100 ng/mL (Figure 18). Across a panel of eight cancer cell lines it raised p53 by up to 5.35-fold (Panc-1), 5.13-fold (MDA-MB) and 3.41-fold (BCFA) (Table 14). [18] The analogy to Peto's paradox is functional rather than genetic: whereas the elephant carries ~20 germline TP53 copies, Metadichol elevates p53 expression and co-induces its tumor-suppressor partner Klotho. Consistent with a protective effect, elevating p53 in already-transformed cells favors cell-cycle arrest and apoptosis, in keeping with tumor suppression in that context.




Figure 18. Metadichol induces p53 (TP53) dose-dependently in normal human dermal fibroblasts (NHDF), reaching 4.11-fold at 100 ng/mL (qRT-PCR, $2^{(-\Delta\Delta Cq)}$; fold change vs untreated control, dashed line).

Table 14. p53 (TP53) fold regulation by Metadichol across cancer cell lines (qRT-PCR).

Cell line	1 pg/mL	100 pg/mL	1 ng/mL	100 ng/mL
Jurkat	1.19	1.66	0.90	0.97
Panc-1	1.59	5.35	3.23	1.27
U87MG	1.38	1.08	0.26	0.33
A549	0.59	1.20	2.97	1.44
SKOV3	0.95	0.31	0.79	0.15
HT-29	1.74	2.22	0.11	0.27
MDA-MB	1.47	3.73	5.13	1.80
BCFA	1.09	1.19	0.93	3.41

This p53 induction is reinforced by Metadichol’s parallel upregulation of the anti-aging protein Klotho, itself a tumor suppressor that restrains IGF-1 and Wnt signaling and promotes cancer-cell death. Across the same cancer-cell panel, Metadichol increased Klotho by up to 12.74-fold (MDA-MB), 11.55-fold (HT-29) and 8.94-fold (Jurkat) (Table 15). The convergence of amplified p53 activity and restored Klotho expression provides a two-pronged, elephant-inspired tumor-suppressive tone in human cells (Figure 19). [18,28]




Figure 19. Metadichol® Master Regulator Gene Network: Orchestrating Anti-Cancer Immunity Through Klotho–ALP Axis. The cascade from Metadichol through VDR inverse agonism, Klotho upregulation (4–10×), ALP induction, and TP53 amplification (up to 5.35×) drives 12 therapeutic outcomes (dark green). Nodes #11 (NK Cell Reactivation) and #12 (DNA Damage Surveillance) represent outcomes newly documented in this manuscript. Red arrows indicate inhibitory relationships (mTOR↓, NF-κB↓); black arrows indicate activation. HCS = 12/12 hallmarks addressed.

Table 15. Klotho fold regulation by Metadichol across cancer cell lines (qRT-PCR).

Cell line	1 pg/mL	100 pg/mL	1 ng/mL	100 ng/mL
Jurkat	0.33	1.13	3.61	8.94
Panc-1	1.66	1.91	1.18	1.31
U87MG	1.01	0.91	0.56	1.75
A549	2.35	4.11	2.73	6.06
SKOV3	0.82	2.03	0.89	1.84
HT-29	11.55	2.68	0.33	4.03
MDA-MB	3.00	5.08	12.74	1.93
BCFA	2.04	1.71	0.97	1.38

Importantly, the same Metadichol–Sirtuins study that documented coordinated induction of Sirtuins 1–7 in somatic and cancer cells also reported this p53 upregulation across the identical cancer-cell panel, [18] placing both readouts within one experimental framework. The coupling is mechanistically apt: SIRT1 is a direct regulator of p53 through deacetylation of its C-terminal lysine residues, and the sirtuin–p53 axis sits at the intersection of metabolic and epigenetic control on one

side and the genome-guardian DNA-damage response on the other. Metadichol’s simultaneous induction of Sirtuins 1–7, p53 and Klotho in the same cells therefore engages several convergent tumor-suppressive and longevity nodes at once, reinforcing—rather than duplicating—the multi-target, hallmark-spanning mechanism described throughout this review.

That same study measured a coordinated 12-gene panel in cancer cells—the seven sirtuins (SIRT1–7) together with Klotho, TERT, TP53, FOXO1 and GDF11. [18] Metadichol’s effect on GDF11 was genuinely cell-context-dependent (Table 16): it induced GDF11 strongly in several lines—peaking at 21.71-fold in MDA-MB-231 breast carcinoma, 7.41-fold in A-549 lung carcinoma and 4.92-fold in SKOV3 ovarian carcinoma—while reducing it in Jurkat, leukemia and Panc-1 pancreatic carcinoma. GDF11, a TGF- β –superfamily factor discussed elsewhere in this review as a systemic rejuvenation signal linked to stem-cell renewal and organ maintenance (Sections 3.4 and 3.6), has documented antiproliferative and pro-apoptotic activity in several tumor types—including breast, colorectal and pancreatic carcinoma—through SMAD2/3 signaling, yet is tumor-promoting in other settings; its role in cancer is aptly described as a “friend or enemy” paradox. [178,179] This mixed, line-specific response is therefore best read as an extension of Metadichol’s broad systemic-rejuvenation and genome-protective tone rather than as a uniform tumor-suppressor effect on the level of p53 or Klotho.

Table 16. GDF11 fold regulation by Metadichol across cancer cell lines (qRT-PCR).

Cell line	1 pg/mL	100 pg/mL	1 ng/mL	100 ng/mL
Jurkat	0.33	1.24	0.71	0.32
Panc-1	0.35	0.50	0.31	0.24
U87MG	1.72	3.81	2.48	1.83
A-549	2.58	2.43	2.35	7.41
SKOV3	0.50	0.53	1.67	4.92
HT-29	1.15	1.74	0.18	0.59
MDA-MB-231	2.94	4.17	21.71	3.99
BCFA	0.80	0.64	2.81	2.10

For aging biology this matters beyond oncology. Genomic instability is a primary hallmark of aging, and a robust p53-centered DNA-damage response is a shared feature of exceptionally cancer-resistant, long-lived species. By re-inducing p53—and Klotho—at picogram-to-nanogram concentrations, without the developmental toxicity that constitutive p53 overexpression causes, Metadichol pharmacologically and reversibly phenocopies the germline TP53 expansion that evolution engineered in elephants. In doing so it narrows the gap between human and elephant cancer resistance while reinforcing the genome-maintenance machinery that is central to healthy aging.

This convergence of genome-guardian and cancer-resistance biology connects the present review to Metadichol’s documented reversal of the Warburg effect — the aerobic glycolysis that Otto Warburg first described in 1927 and that remains a core hallmark of cancer. [180,181] In a companion analysis, the same nuclear-receptor, sirtuin and Klotho programme examined here shifts metabolism from glycolysis toward oxidative phosphorylation, restrains HIF1 α -driven glycolytic genes, and reactivates tumour-suppressor pathways in malignant cells, [59] indicating that the mechanisms maintaining healthy aging and those resisting cancer are, in Metadichol’s case, largely the same. A representative example is the receptor-type tyrosine phosphatase PTPRO, a tumour suppressor silenced by promoter hypermethylation in hepatocellular, lung and other carcinomas, [182–184] which Metadichol reactivates through FOXO transcription factors operating downstream of sirtuin induction [185] — the same SIRT→FOXO axis that underlies its autophagy, stress-resistance and

longevity effects throughout this review. Aging and oncogenesis thus emerge as two faces of one loss of genomic and metabolic homeostasis, both addressed by a single upstream regulator.

12. The 2025 Nobel Prize in Medicine: FOXP3 and Metadichol

The 2025 Nobel Prize in Medicine was awarded for the discovery of regulatory T cells (Tregs) and their master regulator FOXP3. This recognition elevated FOXP3 and the Treg/Teff balance to the centre of immunological science, with profound implications for autoimmune disease, cancer immunotherapy, and, critically for this review, immunosenescence. [108]

Metadichol upregulates FOXP3 by 1.87× in PBMCs, with cross-cellular confirmation in fibroblasts (1.58×) demonstrating that the same molecule produces consistent FOXP3 induction across distinct human cell types. The Treg/Teff balance, governed by the FOXP3 transcriptional program, deteriorates with age, contributing to the paradox of immunosenescence: simultaneous immune exhaustion (reduced effector responses to pathogens) and chronic sterile inflammation (elevated TNF-α, IL-6, HMGB1). [85,92,108]

Metadichol’s simultaneous restoration of FOXP3-mediated regulatory capacity and effector immune function (CD4/CD8 ↑2.0–2.4×, NK-cell factors ↑) represents a uniquely balanced approach to immune rejuvenation, enhancing regulatory suppression of sterile inflammation while maintaining effector responses to genuine threats. [85,108] The broader T-, B-, and NK-cell master-regulator analysis identifies three convergent immune-restoration themes — metabolic universality (PPARγ ↑24.25×, PGC-1α ↑11.08×), effector/regulatory balance (FOXP3-mediated Treg restoration alongside CD4/CD8 ↑2.0–2.4×), and reduced co-stimulatory tone — all achieved at picomolar-to-nanomolar concentrations without disrupting lineage boundaries, while NF-κB-independent IL-15/CD122 signaling adds NK-cell rejuvenation through an anti-inflammatory mechanism suited to chronic use. [85,153,169] The 2025 Nobel Prize positions FOXP3–Treg biology as a frontier of therapeutic development; Metadichol’s documented FOXP3 upregulation at pharmacologically relevant concentrations merits dedicated investigation in autoimmune disease, cancer-immunotherapy adjuvancy, and age-related immunosenescence reversal.

13.1. Comprehensive Coverage Across All Biological Scales

The biological scale framework reveals that no tier of aging biology is left unaddressed by Metadichol. At the genetic scale, TERT is upregulated 16-fold and 31 nucleoporin genes support nuclear pore complex integrity, maintaining the transport machinery for all DNA repair factors. [24,96] At the epigenetic scale, all seven sirtuins (SIRT1–7, 3–15×) together with the complete circadian clock gene network provide the broadest sirtuin coverage of any known compound. [18,150] At the organelle scale, the unique simultaneous regulation of all 13 mitochondrial genome-encoded proteins (Complexes I, III, IV, V) and all 79 ribosomal protein genes addresses bioenergetic and translational fidelity at source — a mechanistic dimension not targeted by any existing anti-aging pharmacological agent. [14,17,85] At the cellular and tissue scales, Yamanaka factor induction (OCT4 ↑19.6×, KLF4 ↑8×, SOX2 ↑6.9×) enables partial cellular rejuvenation without viral vectors, while lineage-fidelity analysis confirms this occurs within existing chromatin accessibility, not through forced lineage switching. [65,85] At the system and functional scales, TERT, SIRT1–7, and Klotho are activated simultaneously — a three-pathway longevity convergence without precedent in a single molecule. [18,24,26,85]

13.2. Systems-Level Regulation: LINE-1, HMGB1, USAG1, and Housekeeping Genes

Three systems-level findings extend Metadichol’s mechanistic scope beyond classical aging pathways. LINE-1 retrotransposon control addresses the age-associated genomic instability and cGAS-STING activation driven by retrotransposon demethylation — a mechanism increasingly implicated in the chronic sterile inflammation of aging. [107] HMGB1 alarmin suppression provides a molecular brake on the SASP feed-forward loop, with direct relevance to frailty and immunosenescence given the well-documented correlation between serum HMGB1 and markers of

biological age. [45,107] The regulation of all 19 housekeeping genes demonstrates that Metadichol's transcriptional reach extends to processes historically considered undruggable, suggesting a fundamentally new class of systems-level modulator acting through nuclear receptor network architecture rather than conventional receptor-effector pharmacology. [59]

13.3. *Safety Profile and the Lineage-Fidelity Paradigm*

A critical concern for any compound activating Yamanaka reprogramming factors is oncogenic risk through aberrant lineage switching. The consistent absence of nine lineage-specific markers (TAL1, PU.1, BLIMP1, P63, MITF, GCM1, FOXJ1, SIM1, PROX1) across all tested concentrations in fibroblast cultures confirms that Metadichol activates master regulatory genes within the accessible chromatin landscape of each cell type rather than forcing ectopic lineage identity. [85] This lineage-fidelity property, combined with GRAS status, 18–24 month rodent carcinogenicity studies showing no neoplastic transformation, and a food-derived composition (long-chain alcohols from rice, sugar cane, wheat, and peanuts), establishes a safety foundation that no synthetic anti-aging compound currently matches. [148,149]

13.4. *Comparative Position and Clinical Translation*

Against the four most studied anti-aging pharmacological agents, Metadichol's multi-target profile is categorically distinct. Resveratrol activates primarily SIRT1; metformin targets AMPK and mitochondrial Complex I; rapamycin inhibits mTOR; NAD⁺ precursors support sirtuin activity. Each addresses 1–3 molecular nodes. Metadichol simultaneously addresses all twelve hallmarks, all eight biological scales, and 13+ independent molecular targets — engaging pathways that converge on the same endpoints from multiple directions. [2,5,85] This breadth also presents the central challenge for clinical translation: conventional single-endpoint trial designs cannot capture multi-target benefit. Biological age clocks (Horvath methylation clock, GrimAge, PhenoAge), multi-omic panels, and frailty indices will be necessary as primary or co-primary endpoints. Priority populations for clinical investigation include immunosenescent older adults (leveraging the FOXP3/NK cell findings), individuals with metabolic syndrome (PPAR γ axis), and those with early neurodegenerative risk (NPC/nucleoporin biology). [9,85,96]

14. **Evolutionary Roots: Are Policosanols Primordial Signaling Molecules?**

A striking implication of Metadichol's pharmacology is the sheer antiquity of the machinery it engages, which invites a question reaching beyond aging into the origins of biological regulation itself. Metadichol is active in human cells across the picomolar-to-nanomolar range (0.1 pg/mL–100 ng/mL), and preliminary observations indicate that it induces germination in the seeds of ancient plant lineages — including lotus and Ginkgo biloba — at comparable ultra-low concentrations. At picogram levels there are far too few molecules to coat membranes or serve as a bulk structural component, so the effect must be receptor- or catalytically-mediated with signal amplification rather than physical. That the same ultra-low, receptor-grade sensitivity should operate in cells as divergent as a human leukocyte and a gymnosperm seed implies that the responsive mechanism predates the plant–animal divergence (~1.5 billion years ago), pointing to an ancestral regulatory function rather than a lineage-specific one.

Consistent with this, the pathways Metadichol modulates are among the most deeply conserved in cellular life. The integrated stress response it activates through ATF4 is built on bZIP transcription factors and eIF2 α phosphorylation present in all eukaryotes and conserved across more than 1.5 billion years (Section 2.5). [58] The heat-shock/chaperone network it coordinately induces (Section 2.4) is older still: HSP70-family proteins are essentially universal, span all three domains of life, and are confidently assigned to the last universal common ancestor. [186] The nuclear-receptor superfamily through which Metadichol acts is thought to have evolved from ancient lipid sensors whose original role was to read environmental and dietary lipids as indicators of cellular conditions,

and VDR-like receptors occur in invertebrates, implying pre-vertebrate origins. [187] The circuits Metadichol engages are therefore not recent innovations but some of the oldest regulatory systems in biology — raising the possibility that their ligands, or ligand-like molecules, are correspondingly ancient.

Policosanols themselves are prebiotically plausible. Long-chain aliphatic alcohols (C24–C34) can form abiotically through Fischer–Tropsch-type synthesis at hydrothermal vents, fatty-acid reduction, serpentinization and meteoritic delivery, [188] and their amphipathic structure would have made them useful to the earliest membranes — partitioning into fatty-acid vesicles, increasing rigidity and buffering against thermal and permeability stress. [189,190] This suggests a route by which a passive membrane constituent could have become an active regulator: policosanols first stabilised protocell membranes physically; changes in membrane fluidity then influenced embedded proteins; cells evolved sensors to detect those states; and those sensors became the ancestors of the nuclear-receptor superfamily, internalising and refining the response over billions of years. On this reading policosanol signalling would be a “biochemical fossil” — a functional regulatory circuit preserved from early life, much as *Ginkgo biloba* is a morphological living fossil — and one of the molecular bridges by which chemistry became biological information processing.

A second, biosynthetic line of reasoning places policosanols even closer to the metabolic core of early life. The long-chain alcohols that make up Metadichol are not exotic products but the natural output of the most ancient carbon-fixing chemistry known. Under the reducing atmosphere of the early Earth, the reductive acetyl-CoA (Wood–Ljungdahl) pathway condensed hydrogen and carbon dioxide directly into acetyl-CoA ($4\text{H}_2 + 2\text{CO}_2 + \text{HS-CoA} \rightarrow \text{CH}_3\text{CO-S-CoA} + 3\text{H}_2\text{O}$; $\Delta G'^{\circ} \approx -59 \text{ kJ/mol}$), a reaction that is thermodynamically favourable even without enzymes and is widely regarded as a chemical relic of life's origin. [191] Acetyl-CoA is in turn the universal precursor of amino acids, carbohydrates, nucleotides and lipids, and therefore serves as a paradigm for the molecular logic of the most ancient pathways. [191] From this same node, fatty-acid synthase builds a C16 acid that undergoes repetitive two-carbon elongation to very-long-chain (C18–C32) acyl-CoAs; a two-step fatty-acyl-CoA reductase then reduces the acyl group first to a fatty aldehyde and then to a primary alcohol, yielding precisely the C24–C34 policosanols present in

Metadichol, which may be further esterified with fatty acids to form waxes. [192] Placing policosanol synthesis a single short extension away from acetyl-CoA — rather than treating it as a late botanical specialisation — implies that these molecules were accessible to cells from the earliest stages of metabolism, and that once cyanobacterial oxygenic photosynthesis reshaped the atmosphere roughly 2.5 billion years ago the same FAS/FAR route was elaborated across the tree of life. This biosynthetic proximity to the oldest node in metabolism reinforces the plausibility of an ancient signalling role for policosanols (Figure 20).

Figure 20 — Policosanols are a short biosynthetic step from acetyl-CoA

From the most ancient carbon-fixing chemistry to the C24–C34 alcohols of Metadichol




Figure 20. Policosanols are a short biosynthetic step from acetyl-CoA, the oldest metabolic node. Under the reducing early-Earth atmosphere, the reductive acetyl-CoA (Wood–Ljungdahl) pathway fixes CO₂ and H₂ into acetyl-CoA — the universal precursor of amino acids, carbohydrates, nucleotides and lipids. Fatty-acid synthase then builds a C16 acid that is elongated in two-carbon steps to C18–C32 acyl-CoAs; a two-step fatty-acyl-CoA reductase (FAR) yields the C24–C34 fatty alcohols (policosanols) that are the active components of Metadichol, which may be esterified to waxes. The route places policosanol production one short extension from the most ancient carbon-fixing chemistry, consistent with an ancient origin for policosanol signalling. Reaction thermodynamics and the acetyl-CoA framing follow Flügel (2011);¹⁹⁵ the FAS/FAR steps follow Rowland and Domergue (2012).¹⁹⁶

This proposal is explicitly a hypothesis, framed to be falsifiable rather than assumed. Its strongest form — that policosanols are primordial homeostatic regulators — predicts that Metadichol should act not only in plants and animals but across all domains of life. A coordinated test in bacteria (for example *Bacillus* sporulation and germination, itself an ancient dormancy–awakening system paralleling seed biology), [193] archaea and early-branching protists, showing responses in the same picogram-to-nanogram window with the biphasic dose–response characteristic of an evolved ligand, would constitute strong evidence, whereas a random or absent cross-domain pattern would refute it (Figure 21). Three cautions are essential. Convergent evolution is an alternative but is unlikely given nearly identical effective concentrations across kingdoms and target pathways that are homologous rather than merely analogous. Horizontal gene transfer could spread a receptor but does not account for protocell-level membrane effects and is inconsistent with the vertical-descent pattern of nuclear-receptor evolution. Most importantly, the possibility that the sub-60-nm nano-emulsion vehicle — rather than the policosanols themselves — drives the effects must be excluded by testing empty vehicle, free (non-emulsified) policosanols and other long-chain alcohols in parallel. The evolutionary reading also connects to other threads of this review, including the species-dependent handling of

the ancestral GULO ascorbate pathway (Section 10) and the deep-time framing of TP53-based cancer resistance (Section 11). Whether or not the primordial-regulator hypothesis survives testing, it reframes Metadichol’s breadth as an expected consequence of engaging biology’s oldest control systems rather than a pharmacological anomaly.

Figure 21 — A cross-domain test of the primordial-signaling hypothesis

If policosanol sensing is ancestral, Metadichol should act across all domains of life in the same picogram–nanogram window.




Figure 21. A cross-domain test of the primordial-signaling hypothesis. If policosanol sensing is an ancestral homeostatic mechanism, Metadichol should engage the same stress and dormancy pathways across all three domains of life within a shared picogram-to-nanogram window. The framework maps a single decisive prediction onto a phylogenetic panel: bacteria (*E. coli*, *B. subtilis*; heat-shock σ^{32} and sporulation–germination), archaea (*Haloferax*, *Sulfolobus*; stress and membrane adaptation), and eukaryotic protists (*Tetrahymena*, *Giardia*; HSP induction and encystation) and plants (*lotus*, *Ginkgo* seeds; germination) are proposed tests, whereas the eukaryotic-animal arm is already demonstrated in human PBMCs (ATF4 and PTPRO induction, this work). A conserved biphasic response peaking at 1–100 pg/mL across all systems would support an ancient regulator (H1); a random or absent cross-domain pattern would refute it (H4).

A recent analysis frames the ultimate ceiling on human lifespan in thermodynamic terms: somatic mutations accumulate stochastically and irreversibly, behaving as a form of genomic entropy that imposes a binding upper bound on longevity even if every other aging process were corrected (Table 17). [194] This reframing is useful for situating Metadichol, because aging is itself organized across nested scales — molecular, cellular and systemic — with damage originating at the molecular level and propagating upward to cellular dysfunction and organism-wide decline. [195] A single-target agent acts at one point in this hierarchy; the evidence reviewed here indicates that Metadichol acts at all three scales at once (Figure 22; Table 18).




Figure 22. Metadichol acts across the three scales of aging. Damage originates at the molecular scale (the source of somatic-mutation entropy) and propagates upward to cellular and systemic decline; Metadichol’s documented mechanisms intervene at each scale. The somatic-mutation ceiling (Efimov et al., 2026) is a fundamental limit that these mechanisms may slow but cannot abolish. Framework adapted from Guo et al. (2022).

Table 17. Aging across scales: the somatic-mutation entropy bound.

HIGHLIGHTS
• Somatic mutations impose an entropic ceiling on lifespan — a binding constraint (~194 years even if all other aging processes were corrected; Efimov et al., 2026).
• Aging is organized across molecular, cellular and systemic scales, and Metadichol’s documented mechanisms act at all three simultaneously.
• Two anti-entropy levers operate together: slowing mutation production (DNA repair, ROS reduction, LINE-1 control) and clearing damaged cells (p53, immune surveillance) — powered by restored NAD⁺ and OXPHOS.
• The entropic limit can be approached and slowed, not repealed; present evidence is transcriptional and in vitro.

Table 18. Metadichol’s documented mechanisms mapped to the three scales of aging.

Scale	Aging drivers	Metadichol response
Molecular	Genomic instability; telomere shortening; epigenetic alteration; proteostasis loss; compromised autophagy;	SIRT6 DSB repair; LINE-1 silencing; TERT; sirtuin epigenetic reset; 22-gene HSF1/SIRT1 chaperones; PGC-1α / SIRT3 / Nrf2, ROS ↓

	mitochondrial dysfunction / ROS	
Cellular	Cellular senescence & SASP; stem-cell exhaustion; altered intercellular communication	NF-κB-independent TNF-α ↓ / NLRP3 ↓; non-viral Yamanaka factors; HMGB1 ↓ / IL-15 / NK clearance; p53 & immune surveillance
Systemic	Nutritional dysregulation / nutrient sensing; IGF axis; gut–brain axis / dysbiosis	mTOR ↓ (CR-mimetic) / AMPK / FOXO; Klotho ↑ / NAD ⁺ salvage supported (CLOCK–BMAL1 → NAMPT); VDR engagement / microbiome; metabolic & immune restoration

At the molecular scale — where somatic-mutation entropy originates — Metadichol engages the machinery that both limits new damage and repairs it: coordinated induction of the sirtuin family including SIRT6, a principal driver of DNA double-strand-break repair (Section 2.1); silencing of LINE-1 retrotransposons that would otherwise contribute insertional mutations (Section 8.1); telomerase/TERT support; sirtuin-driven epigenetic maintenance; the 22-gene HSF1/SIRT1 chaperone network (Section 2.4); and restoration of mitochondrial function through PGC-1α, SIRT3 and Nrf2 with a corresponding reduction in reactive oxygen species. Because oxidative damage is a primary endogenous mutagen, lowering it lowers the rate at which somatic mutations form — acting directly on the entropic source.

At the cellular scale — where molecular damage is amplified — Metadichol dampens the senescence-associated secretory phenotype through NF-κB-independent suppression of TNF-α and NLRP3, supports stem-cell renewal via non-viral induction of the Yamanaka reprogramming factors, and promotes clearance of damaged and transformed cells through the TP53 genome-guardian programme (Section 11) and NK/immune surveillance (Sections 5–6). At the systemic scale it restrains mTOR in a caloric-restriction-like manner, induces Klotho, restores NAD⁺ by supporting clock-driven NAD⁺ salvage, and engages the vitamin D receptor with its links to microbiome balance. Two anti-entropy levers therefore operate together — slowing the production of molecular disorder and removing the disordered cells it generates — both of which are energy-dependent and are supported by Metadichol’s restoration of NAD⁺ and oxidative-phosphorylation capacity.

This multi-scale action does not repeal the entropic limit. Somatic mutations are stochastic and cumulative, the present evidence for Metadichol is largely transcriptional and in vitro, and no lifespan or somatic-mutation-rate data are yet available. What the framework does suggest is that Metadichol’s breadth is well matched to the structure of the problem: by addressing the many mechanisms that would otherwise curtail life before the mutational ceiling is reached, and by plausibly flattening the molecular entropy curve, it is the kind of intervention that could allow the mutation-limited regime to be approached rather than bypassing it. [194]

Limitations and Future Directions

The current evidence base spans in vitro studies across multiple human cell lines, Q-RT-PCR profiling with corroborating Western blots, and open-label case series. The main opportunities to further strengthen the case are:

- (i) Causal ordering of the proposed five-level cascade (VDR → nuclear receptors → sirtuins → Klotho → TLR/FOX/KLF → circadian) through receptor knockdown/knockout and time-course studies;
- (ii) In vivo and functional endpoints, including health span/lifespan and biological-age biomarkers;

- (iii) randomized controlled human trials;
- (iv) Direct confirmation of the ascorbate-recycling mechanism and its effect on serum Vitamin C;
- (v) Continued independent replication.

A further limitation concerns normalization. The qRT-PCR data reported here and in the companion studies are normalized to GAPDH alone, and the quantification cycles indicate that the GAPDH signal is not invariant under Metadichol treatment. This is consistent with our own geNorm analysis of the chaperone-network dataset, in which GAPDH was found to be unstable, was excluded, and was replaced by the geometric mean of HPRT1 and RPLP0. Where reference-gene abundance shifts, fold-changes for genes whose own transcript levels are stable will be depressed and apparent suppression may be overstated; the CD38 series discussed in Section 2.5 is one such case. Effects of large magnitude are unlikely to be explained on these grounds, but modest changes and reported suppressions should be regarded as provisional until the panels are re-normalised against a validated multi-gene reference, for which the geometric mean of HPRT1 and RPLP0 is our preferred choice. Where a small number of mRNA/protein discordances occur (for example PGC1 α , controlled by miR-696/miR-23a), they reflect recognized post-transcriptional regulation rather than absence of effect. Addressing these points would consolidate an already substantial, protein-corroborated body of work into a definitive, mechanistically grounded case for human clinical investigation. [85,107,108,172]

Conclusions

Metadichol is best understood not as a single-pathway drug but as a **systems-level regulator of aging**. From one upstream event — inverse/protean agonism of the vitamin D receptor (VDR) — it reprograms an interconnected network, engaging the best-validated anti-aging pathways (the sirtuins SIRT1–7, telomerase, Klotho, FOXO, mTOR-modulated autophagy, the NAD⁺ pathway and PGC-1 α) and *inducing the Yamanaka reprogramming factors without viral vectors*. It acts at both transcript and Western-blot-confirmed protein levels across nuclear-receptor, sirtuin, Klotho, TLR/FOX/KLF and circadian program, modulating more than 2,300 genes and all 49 nuclear receptors. [2,96,113,114]

Its defining property is **coordination**. Picogram-to-nanogram activity is amplified through the HSF1/SIRT1, sirtuin and PGC-1 α hubs into concerted control of the systems that fail together in aging — **immunity** (restored FOXP3/Treg balance with CD4/CD8 effectors, CD28 re-induction and NK-cell maturation via CD122/IL-15), **inflammation** (TNF- α , NF- κ B and HMGB1 suppression), **proteostasis** (the HSF1/SIRT1 chaperone network) and **metabolism** (PGC-1 α -driven mitochondrial biogenesis with clock-linked support of the NAD⁺ salvage pathway). Because these anti-aging pathways and systems converge on shared longevity nodes and map onto the twelve hallmarks of aging, Metadichol behaves as an upstream, pan-nuclear-receptor coordinator that restores baseline resilience — a rationale for combining it with more targeted agents. [51]

Realizing this potential will require moving beyond transcript-level, short-term culture data to functional and in vivo validation — protein- and metabolite-level confirmation (for example, direct intracellular NAD⁺ quantification), loss-of-function testing of the proposed VDR/HSF1 upstream axis, and randomized controlled clinical evaluation within the narrow hormetic dose window. [196,197] Should these steps confirm the signatures reported here, Metadichol’s simultaneous, low-dose engagement of multiple anti-aging pathways and hallmarks — as a **system regulator rather than a single-target agent** — would be a distinctive and complementary addition to the Geroscience toolkit alongside caloric-restriction mimetics, Senolytics and partial-reprogramming approaches. [88]

Supplementary; All work regarding Metadichol was carried out by commercial CRO;s on a fee for service basis to eliminate bias in our results.

P.R. Raghavan is founder and Founder and CEO of Nanorx Inc., which develops Metadichol. This relationship is disclosed per standard journal conflict-of-interest policies.

Additional Information is available on request

Abbreviations

Abbreviations are listed alphabetically. Gene names follow HGNC nomenclature; protein names follow standard biochemical convention.

Abbreviation	Definition
ACE	Angiotensin-Converting Enzyme
ADP	Adenosine Diphosphate
AMP	Antimicrobial Peptide (e.g., cathelicidin, β -defensins)
AMPK	AMP-Activated Protein Kinase
ATG16L1	Autophagy-Related 16-Like 1 (VDR-regulated autophagy effector)
ATP	Adenosine Triphosphate
BAG3	BCL2-Associated Athanogene 3 (chaperone-assisted selective autophagy)
BCAT1	Branched-Chain Amino Acid Transaminase 1
BECN1	Beclin-1 (core autophagy-initiation regulator)
BLIMP1	B Lymphocyte-Induced Maturation Protein 1
BMAL1	Brain and Muscle ARNT-Like 1 (core circadian clock gene)
BMP	Bone Morphogenetic Protein
CAR	Constitutive Androstane Receptor
CDKN1A/p21	Cyclin-Dependent Kinase Inhibitor 1A
cGAS-STING	Cyclic GMP-AMP Synthase – Stimulator of Interferon Genes
CLOCK	Circadian Locomotor Output Cycles Kaput
CRY1/2	Cryptochrome 1/2 (circadian repressors)
DAMP	Damage-Associated Molecular Pattern
DDIT4/REDD1	DNA Damage-Inducible Transcript 4 / Regulated in Development and DNA Damage Response 1 (mTORC1 inhibitor)
DNMT	DNA Methyltransferase
EZH2	Enhancer of Zeste Homolog 2 (PRC2 catalytic subunit)
FOXJ1	Forkhead Box J1 (ciliated cell marker)
FOXO	Forkhead Box O (longevity transcription factor)

Abbreviation	Definition
FOXP3	Forkhead Box P3 (Treg master regulator; 2025 Nobel Prize in Physiology or Medicine)
FXR	Farnesoid X Receptor
GCM1	Glial Cells Missing Transcription Factor 1 (placental marker)
GDF11	Growth Differentiation Factor 11 (rejuvenation factor)
GPR120/FFAR4	G-Protein Coupled Receptor 120 / Free Fatty Acid Receptor 4
GRAS	Generally Recognized As Safe
GR	Glucocorticoid Receptor
GULO	L-Gulonolactone Oxidase (Vitamin C biosynthesis enzyme)
HDAC	Histone Deacetylase
HIF	Hypoxia-Inducible Factor
HMGB1	High Mobility Group Box 1 (alarmin / DAMP; senescence mediator)
IGF-1	Insulin-Like Growth Factor 1
IL-6	Interleukin-6
IL-15	Interleukin-15 (NK cell survival and maturation cytokine)
IL-15R α /CD122	Interleukin-15 Receptor Alpha / CD122 (IL-2/15 receptor β -chain)
iPSC	Induced Pluripotent Stem Cell
JAK-STAT	Janus Kinase – Signal Transducer and Activator of Transcription
KLF	Krüppel-Like Factor family
KLF4	Krüppel-Like Factor 4 (Yamanaka reprogramming factor)
LINE-1	Long Interspersed Nuclear Element 1 (retrotransposon, ~17% of human genome)
LC3	Microtubule-Associated Protein 1 Light Chain 3 (autophagosome marker)
LXR	Liver X Receptor
MITF	Melanocyte Inducing Transcription Factor (melanocyte lineage marker)
mtDNA	Mitochondrial DNA
MT-ATP6/8	Mitochondrial ATP Synthase Subunits 6 and 8 (Complex V)
MT-CO1-3	Mitochondrial Cytochrome c Oxidase Subunits 1–3 (Complex IV)

Abbreviation	Definition
MT-CYB	Mitochondrial Cytochrome b (Complex III)
MT-ND1-6	Mitochondrial NADH Dehydrogenase Subunits 1–6 (Complex I)
mTOR	Mechanistic Target of Rapamycin
NAD ⁺	Nicotinamide Adenine Dinucleotide (oxidised; sirtuin cofactor)
NF-κB	Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
NHDF	Normal Human Dermal Fibroblasts
NK	Natural Killer cell
NMN	Nicotinamide Mononucleotide (NAD ⁺ precursor)
NLRP3	NLR Family Pyrin Domain Containing 3 (inflammasome sensor)
NPC	Nuclear Pore Complex
NR	Nuclear Receptor (49 known members in humans)
NUP	Nucleoporin (nuclear pore complex structural protein)
OCT4/POU5F1	Octamer-Binding Transcription Factor 4 (Yamanaka factor)
P63	Tumour Protein P63 (epithelial stem cell marker)
PARP	Poly(ADP-Ribose) Polymerase
PBMC	Peripheral Blood Mononuclear Cell
PER1/2/3	Period Circadian Regulator 1/2/3 (circadian clock components)
PGC1α	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (mitochondrial biogenesis)
PPARγ	Peroxisome Proliferator-Activated Receptor Gamma (metabolic master regulator)
PROX1	Prospero Homeobox 1 (lymphatic endothelial marker)
PU.1	Purine-Rich Box 1 (myeloid/B-cell master regulator)
Q-RT-PCR	Quantitative Real-Time Polymerase Chain Reaction
RAGE	Receptor for Advanced Glycation End-products
ROS	Reactive Oxygen Species
RPL	Ribosomal Protein Large subunit (RPL1–40 family)
RPS	Ribosomal Protein Small subunit (RPS2–30 family)

Abbreviation	Definition
SASP	Senescence-Associated Secretory Phenotype
SIM1	Single-Minded Homolog 1 (hypothalamic lineage marker)
SIRT1-7	Sirtuin 1–7 (NAD ⁺ -dependent deacetylases; longevity regulators)
SOD2	Superoxide Dismutase 2 (mitochondrial antioxidant enzyme)
SOX2	SRY-Box Transcription Factor 2 (Yamanaka factor / neural stem cell regulator)
SOX	SRY-Box Transcription Factor family
TAL1	T-Cell Acute Lymphocytic Leukaemia Protein 1 (haematopoietic lineage marker)
Teff	Effector T Cell
TERT	Telomerase Reverse Transcriptase
TERC	Telomerase RNA Component
TET	Ten-Eleven Translocation methylcytosine dioxygenase (epigenetic demethylase)
TFEB	Transcription Factor EB (master regulator of autophagy-lysosome biogenesis)
TGF-β	Transforming Growth Factor-Beta
TLR	Toll-Like Receptor (innate immune sensor)
TMPRSS2	Transmembrane Serine Protease 2
TNF-α	Tumour Necrosis Factor-Alpha
TP53/p53	Tumour Protein P53 (genome guardian)
Treg	Regulatory T Cell
USAG1	Uterine Sensitization-Associated Gene 1 / Sostdc1 (BMP antagonist)
VDR	Vitamin D Receptor
VDBP	Vitamin D Binding Protein
HSF1	Heat shock factor 1
HSF2	Heat shock factor 2
HSP	Heat shock protein
HSP70	70 kDa heat shock protein family (HSPA)
HSP90	90 kDa heat shock protein family (HSPC)
BiP	Binding immunoglobulin protein (HSPA5); ER master chaperone

Abbreviation	Definition
gp96	Glucose-regulated protein 96 (HSP90B1); ER HSP90
STIP1/HOP	Stress-induced phosphoprotein 1; HSP70–HSP90 organizing protein
CDC37	Cell division cycle 37; kinase-specific HSP90 co-chaperone
UPR	Unfolded protein response
UPRmt	Mitochondrial unfolded protein response
geNorm	Geometric-averaging reference-gene stability algorithm

References

1. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol.* 2012;22(17):R741-R752. doi:10.1016/j.cub.2012.07.024

2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* 2013;153(6):1194-1217. doi:10.1016/j.cell.2013.05.039

3. Wei W, Li T, Chen J, et al. SIRT3/6: an amazing challenge and opportunity in the fight against fibrosis and aging. *Cell Mol Life Sci.* 2024;81(1):69. doi:10.1007/s00018-023-05093-z

4. Tian X, Firsanov D, Zhang Z, et al. SIRT6 is responsible for more efficient DNA double-strand break repair in long-lived species. *Cell.* 2019;177(3):622-638.e22. doi:10.1016/j.cell.2019.03.043

5. Papadopoli D, Boulay K, Kazak L, et al. mTOR as a central regulator of lifespan and aging. *F1000Res.* 2019;8:F1000 Faculty Rev-998. doi:10.12688/f1000research.17196.1

6. Mannick JB, Morris M, Hlatky MA, et al. Targeting the biology of aging with mTOR inhibitors. *Nat Med.* 2023;29(5):1126-1139. doi:10.1038/s41591-023-02330-y

7. Lee DJW, Woodward O, Wu P, Yao W. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. *Lancet Healthy Longev.* 2024;5(1):e33-e46. doi:10.1016/S2666-7568(23)00258-1

8. Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. *Aging Cell.* 2016;15(2):196-207. doi:10.1111/accel.12424

9. Du S, Zheng S, Wang L, et al. Role of FoxO transcription factors in aging and age-related metabolic and neurodegenerative diseases. *Cell Biosci.* 2021;11(1):199. doi:10.1186/s13578-021-00700-7

10. Irmak S, Dunford NT, Milligan J. Policosanol contents of beeswax, sugar cane and wheat extracts. *Food Chem.* 2006;95(2):312-318. doi:10.1016/j.foodchem.2005.01.009

11. Raghavan PR. Policosanol Nanoparticles. US Patents 8,722,093 (May 13, 2014); 9,034,383 (May 19, 2015); 9,006,292 (April 14, 2015).

12. Raghavan PR. Metadichol® a novel nano lipid formulation. *Research Outreach.* 2021. <https://researchoutreach.org/articles/metadichol-novel-nano-lipid-formulation/>

13. Mijit M, Caracciolo V, Melillo A, et al. Role of p53 in the Regulation of Cellular Senescence. *Biomolecules.* 2020;10(3):420. doi:10.3390/biom10030420

14. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. *Oncogene.* 2013;32(43):5129-5143. doi:10.1038/onc.2012.640

15. Feng Z, Lin M, Wu R. The Regulation of Aging and Longevity: A New and Complex Role of p53. *Genes Cancer.* 2011;2(4):443-452. doi:10.1177/1947601911410223

16. Mangerich A, Bürkle A. Pleiotropic cellular functions of PARP1 in longevity and aging. *Front Genet.* 2012;3:247. doi:10.3389/fgene.2012.00247

17. Rouleau-Turcotte É, Krastev DB, Pettitt SJ, Lord CJ, Pascal JM. ADP-ribose contributions to genome stability and PARP inhibitor synthetic lethality. *J Biol Chem.* 2023;299(11):105280. doi:10.1016/j.jbc.2023.105280

18. Raghavan PR. Metadichol®-induced expression of Sirtuins 1-7 in somatic and cancer cells. *Med Res Arch.* 2024;12(6). doi:10.18103/mra.v12i6.5328

19. Linster CL, Van Schaftingen E. Vitamin C: biosynthesis, recycling and degradation in mammals. *FEBS J.* 2007;274(1):1-22. doi:10.1111/j.1742-4658.2006.05607.x

20. Li Z, Zhang W, Chen Y, et al. Impaired DNA double-strand break repair contributes to the age-associated rise of genomic instability in humans. *Cell Death Differ.* 2016;23(11):1765-1777. doi:10.1038/cdd.2016.65

21. Blackburn EH, Epel ES, Lin J. Human telomere biology. *Science.* 2015;350(6265):1193-1198. doi:10.1126/science.aab4438

22. Shay JW, Wright WE. Telomerase therapeutics for cancer. *Nat Rev Drug Discov.* 2006;5(7):577-584. doi:10.1038/nrd2081

23. Rossiello F, Jurk D, Passos JF, d’Adda di Fagagna F. Telomere dysfunction in ageing and age-related diseases. *Nat Cell Biol.* 2022;24(2):135-147. doi:10.1038/s41556-022-00842-x

24. Raghavan PR. The quest for immortality: Introducing Metadichol®, a novel telomerase activator. *J Stem Cell Res Ther.* 2019;9:446. doi:10.4172/2157-7633.1000446

25. Shim HS, Horner JW, Wu CJ, et al. TERT activation targets DNA methylation and multiple aging hallmarks. *Cell.* 2024;187(14):3708-3726.e23. doi:10.1016/j.cell.2024.05.035

26. Raghavan PR. Metadichol® a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. *J Cancer Sci Ther.* 2018;10(11):351-357. doi:10.4172/1948-5956.1000566

27. Raghavan PR. Improving longevity with Metadichol® by inhibiting the Bcat-1 gene. *J Aging Sci.* 2017;5(1):174. doi:10.4172/2329-8847.1000174

28. Pal S, Tyler JK. Epigenetics and aging. *Sci Adv.* 2016;2(7):e1600584. doi:10.1126/sciadv.1600584

29. Imai S, Guarente L. It takes two to tango: NAD⁺ and sirtuins in aging/longevity control. *NPJ Aging Mech Dis.* 2016;2:16017. doi:10.1038/npjamd.2016.17

30. Grabowska W, Sikora E, Bielak-Zmijewska A. Sirtuins, a promising target in slowing down the ageing process. *Biogerontology.* 2017;18(4):447-476. doi:10.1007/s10522-017-9685-9

31. You Y, Liang W. SIRT1 and SIRT6: The role in aging-related diseases. *Biochim Biophys Acta Mol Basis Dis.* 2023;1869(8):166815. doi:10.1016/j.bbadis.2023.166815

32. Yoshino J, Baur JA, Imai SI. NAD⁺ Intermediates: The Biology and Therapeutic Potential of NMN and NR. *Cell Metab.* 2018;27(3):513-528. doi:10.1016/j.cmet.2017.11.002

33. Wu QJ, Zhang TN, Chen HH, et al. The sirtuin family in health and disease. *Signal Transduct Target Ther.* 2022;7:402. doi:10.1038/s41392-022-01257-8

34. Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors. *Pharmacol Ther.* 2018;188:140-154. doi:10.1016/j.pharmthera.2018.03.004

35. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. *Cell.* 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001

36. Willcox BJ, Donlon TA, He Q, et al. FOXO3A genotype is strongly associated with human longevity. *Proc Natl Acad Sci U S A.* 2008;105(37):13987-13992. doi:10.1073/pnas.0801030105

37. Golson ML, Kaestner KH. Fox transcription factors: from development to disease. *Development.* 2016;143(24):4558-4570. doi:10.1242/dev.112672

38. Kim HJ, Lee Y, Kim M, et al. Toll-like receptor 4 (TLR4): new insight immune and aging. *Immunity & Ageing.* 2023;20(1):57. doi:10.1186/s12979-023-00383-3

39. Shaw AC, Goldstein DR, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. *Ageing Res Rev.* 2011;10(3):346-353. doi:10.1016/j.arr.2010.10.007

40. Yousefi-Ahmadipour A, Rashidian A, Mirzaei MR, Farsinejad A, Khademizadeh M, Fatemi I. Toll-like receptor 4 and the inflammation during aging. *J Gerontol Geriatr.* 2022;70(3):171-179. doi:10.36150/2499-6564-N538

41. Raghavan PR. Metadichol Orchestrates Cellular Reprogramming and Regenerative Pathways via FOX Transcription Factor Networks: Implications for Immune–Metabolic Rejuvenation. *Med Res Arch.* 2026;14(1). doi:10.18103/mra.v14i1.7160

42. Raghavan PR. Synergistic Targeting of Krüppel-like Factor and Related Signaling Pathways by Metadichol: A Multidimensional Anticancer Strategy. *Med Res Arch.* 2025;13(6). doi:10.18103/mra.v13i6.6583

43. Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. *Nat Rev Mol Cell Biol.* 2019;20(7):421-435. doi:10.1038/s41580-019-0101-y
44. Tavernarakis N. Ageing and the regulation of protein synthesis: a balancing act? *Trends Cell Biol.* 2008;18(5):228-235. doi:10.1016/j.tcb.2008.02.004
45. Calderwood SK, Murshid A, Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging. *Gerontology.* 2009;55(5):550-558. doi:10.1159/000225957
46. Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. *Cell.* 2011;146(5):682-695. doi:10.1016/j.cell.2011.07.030
47. Aman Y, Schmauck-Medina T, Hansen M, et al. Autophagy in healthy aging and disease. *Nat Aging.* 2021;1(8):634-650. doi:10.1038/s43587-021-00098-4
48. García-García V, Calvo-Lobo C, Muñoz-Delgado E, et al. Role of NF-κB in Ageing and Age-Related Diseases. *Int J Mol Sci.* 2021;22(16):8875. doi:10.3390/ijms22168875
49. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Activation of innate immunity system during aging: NF-κB signaling is the molecular culprit of inflamm-aging. *Ageing Res Rev.* 2008;7(2):83-105. doi:10.1016/j.arr.2007.09.002
50. Milman S, Huffman DM, Barzilai N. The Somatotrophic Axis in Human Aging: Framework for Current State of Knowledge and Future Research. *Cell Metab.* 2016;23(6):980-989. doi:10.1016/j.cmet.2016.05.014
51. Raghavan PR. Proteostasis as an integrating node: Metadichol coordinately induces the 22-gene HSF1/SIRT1-anchored chaperone network in human PBMCs at picogram concentrations. *Preprints.* 2026. doi:10.20944/preprints202607.0731.v1
52. Richardson NE, Konon EN, Schuster HS, et al. Lifelong restriction of dietary branched-chain amino acids has sex-specific benefits for frailty and lifespan in mice. *Nat Aging.* 2021;1(1):73-86. doi:10.1038/s43587-020-00006-2
53. Neinast M, Murashige D, Arany Z. Branched Chain Amino Acids. *Annu Rev Physiol.* 2019;81:139-164. doi:10.1146/annurev-physiol-020518-114455
54. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. *Cell Metab.* 2016;23(6):1127-1139. doi:10.1016/j.cmet.2016.05.006
55. Chini CCS, Tarragó MG, Chini EN. NAD and the aging process: role in life, death and everything in between. *Mol Cell Endocrinol.* 2017;455:62-74. doi:10.1016/j.mce.2016.11.003
56. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD⁺ metabolism and its roles in cellular processes during ageing. *Nat Rev Mol Cell Biol.* 2021;22(2):119-141. doi:10.1038/s41580-020-00313-x
57. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. *Science.* 2015;350(6265):1208-1213. doi:10.1126/science.aac4854
58. Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. *EMBO Rep.* 2016;17(10):1374-1395. doi:10.15252/embr.201642195.
59. Raghavan, P.R., 2026. From Undruggable to Therapeutic: Metadichol Selectively Modulates Stress-Responsive Housekeeping Genes in Human Peripheral Blood Mononuclear Cells and Six Cancer Cell Lines. *Medical Research Archives*, [S.l.], v. 14, n. 8, aug. 2026.
60. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. *Proc Natl Acad Sci U S A.* 2004;101(31):11269-11274. doi:10.1073/pnas.0400541101
61. Wortel IMN, van der Meer LT, Kilberg MS, van Leeuwen FN. Surviving stress: modulation of ATF4-mediated stress responses in normal and malignant cells. *Trends Endocrinol Metab.* 2017;28(11):794-806. doi:10.1016/j.tem.2017.07.003
62. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. *Genes Dev.* 2004;18(23):2893-2904. doi:10.1101/gad.1256804
63. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. *Genes Dev.* 2008;22(2):239-251. doi:10.1101/gad.1617608

64. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in *Caenorhabditis elegans*. *Aging Cell*. 2007;6(1):95-110. doi:10.1111/j.1474-9726.2006.00267.x
65. Raghavan PR. Metadichol is a natural ligand for the expression of Yamanaka reprogramming factors in human cardiac, fibroblast, and cancer cell lines. *Med Res Arch*. 2024;12(6):5323. doi:10.18103/mra.v12i6.5323
66. Sun N, Youle RJ, Finkel T. The Mitochondrial Basis of Aging. *Mol Cell*. 2016;61(5):654-666. doi:10.1016/j.molcel.2016.01.028
67. Sun N, Youle RJ, Bharat T. Mitochondria in health and disease. *Nat Rev Mol Cell Biol*. 2016;17(8):563-578. doi:10.1038/nrm.2016.76
68. Tezze C, Romanello V, Desbats MA, et al. Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Force, and Systemic Metabolism. *Cell Metab*. 2017;25(6):1374-1387.e6. doi:10.1016/j.cmet.2017.04.021
69. Busch KB. PGC-1 α is a master regulator of mitochondrial lifecycle. *Antioxidants*. 2023;12(5):1075. doi:10.3390/antiox12051075
70. Itsumi M, Inoue S, Elia AJ, et al. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress. *Cell Death Differ*. 2015;22(11):1837-1845. doi:10.1038/cdd.2015.38
71. Semenza GL. Hypoxia-inducible factors in physiology and medicine. *Cell*. 2012;148(3):399-408. doi:10.1016/j.cell.2012.01.021
72. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1 α . *Mol Cell*. 2010;38(6):864-878. doi:10.1016/j.molcel.2010.05.023
73. Zhong L, D'Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1 α . *Cell*. 2010;140(2):280-293. doi:10.1016/j.cell.2009.12.041
74. Herranz N, Gil J. Mechanisms and functions of cellular senescence. *J Clin Invest*. 2018;128(4):1238-1246. doi:10.1172/JCI95148
75. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? *EMBO Rep*. 2014;15(11):1139-1153. doi:10.15252/embr.201439245
76. López-Domínguez JA, Rodríguez-López S, Ahumada-Castro U, et al. Cdkn1a transcript variant 2 is a marker of aging and cellular senescence. *Aging (Albany NY)*. 2021;13(11):14550-14578. doi:10.18632/aging.203110
77. Yan J, Chen Y, Luo M, Hu X, Li H, Liu Q. The role of p21 in cellular senescence and aging-related diseases. *MedComm (2020)*. 2024;5(5):e558. doi:10.1002/mco2.558
78. Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature*. 2016;530(7589):184-189. doi:10.1038/nature16932
79. Xu M, et al. Senolytics improve physical function and increase lifespan. *Nat Med*. 2018;24(8):1246-1256. doi:10.1038/s41591-018-0092-9
80. Hari P, Millar FR, Tarrats N, et al. The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype. *Sci Adv*. 2019;5(6):eaaw0254. doi:10.1126/sciadv.aaw0254
81. Zhao L, Li Y, Song Y, et al. B2M loss in cancer: mechanisms and therapeutic implications. *Front Immunol*. 2023;14:1219543. doi:10.3389/fimmu.2023.1219543
82. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. *Cell*. 1994;76(2):287-299. doi:10.1016/0092-8674(94)90336-0
83. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science*. 1999;285(5428):727-729. doi:10.1126/science.285.5428.727
84. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. *Cancer Res*. 2011;71(18):5998-6009. doi:10.1158/0008-5472.CAN-10-3211
85. Raghavan PR. Metadichol Orchestrates T, B, and NK Cell Immunity Through Master Regulator Gene Networks. *Med Res Arch*. 2026;14(7). doi:10.18103/mra.2026.0422
86. Schultz MB, Sinclair DA. When stem cells grow old. *Development*. 2016;143(1):3-14. doi:10.1242/dev.130633

87. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. *Cell*. 2013;153(4):828-839. doi:10.1016/j.cell.2013.04.015
88. Ocampo A, Reddy P, Martinez-Redondo P, et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. *Cell*. 2016;167(7):1719-1733.e12. doi:10.1016/j.cell.2016.11.052
89. Raghavan PR. Metadichol induces CD14 glycoprotein expression in human embryonic stem cells and fibroblasts. *Med Res Arch*. 2025;13(5). doi:10.18103/mra.v13i5.6490
90. Fledderus JO, van Thienen JV, Boon RA, et al. Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription. *Blood*. 2007;109(10):4249-4257. doi:10.1182/blood-2006-07-036020
91. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol*. 2018;15(9):505-522. doi:10.1038/s41569-018-0064-2
92. Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. *Signal Transduct Target Ther*. 2023;8(1):200. doi:10.1038/s41392-023-01451-2
93. Raghavan PR. Metadichol® inhibition of TNF- α and NF- κ B. US Patent 8,722,093, issued May 13, 2014.
94. Hood S, Amir S. The aging clock: circadian rhythms and later life. *J Clin Invest*. 2017;127(2):437-446. doi:10.1172/JCI90328
95. Acosta-Rodríguez VA, de Groot MHM, Rijo-Ferreira F, Green CB, Takahashi JS. Importance of circadian timing for aging and longevity. *Nat Commun*. 2021;12(1):2862. doi:10.1038/s41467-021-22922-6
96. Raghavan PR. Metadichol®: a nano lipid emulsion that expresses all 49 nuclear receptors in stem and somatic cells. *Arch Clin Biomed Res*. 2023;7(4):524-536. doi:10.26502/acbr.50170368
97. Kenakin T. Inverse, protean, and ligand-selective agonism. *FASEB J*. 2001;15(3):598-611. doi:10.1096/fj.00-0438rev
98. Hansen M, Rubinsztein DC, Walker DW. Autophagy as a promoter of longevity: insights from model organisms. *Nat Rev Mol Cell Biol*. 2018;19(9):579-593. doi:10.1038/s41580-018-0033-y
99. Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. *Science*. 2011;332(6036):1429-1433. doi:10.1126/science.1204592
100. Raghavan PR. Beyond Rapamycin: Metadichol Represents a New Class of Multi-Target mTOR Modulators. *Med Res Arch*. 2025;13(9). doi:10.18103/mra.v13i9.6876
101. Jin D, Wu S, Zhang YG, et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. *Clin Ther*. 2015;37(5):996-1009.e7. doi:10.1016/j.clinthera.2015.04.004
102. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci*. 2014;69(Suppl 1):S4-S9. doi:10.1093/gerona/glu057
103. Kawahara TLA, Michishita E, Adler AS, et al. SIRT6 links histone H3K9 deacetylation to NF- κ B-dependent gene expression and organismal life span. *Cell*. 2009;136(1):62-74. doi:10.1016/j.cell.2008.10.052
104. Raghavan PR. Metadichol: an agonist that expresses the anti-aging gene Klotho in various cell lines. *Fortune J Health Sci*. 2023;6:357-362. doi:10.26502/fjhs.135
105. Raghavan PR. Metadichol, A Modulator that Controls Expression of Toll Like Receptors in Cancer Cell Lines. *Br J Cancer Res*. 2024;7(3):720-732. doi:10.31488/bjcr.198
106. Raghavan PR. Metadichol-induced expression of Toll receptor family members in PBMCs. *Med Res Arch*. 2024;12(8). doi:10.18103/mra.v12i8.5610
107. Raghavan PR. One Molecule, Three Danger Signals: Metadichol's Systems-Level Coordination of LINE1, HMGB1, and USAG1 for Safe Immune Enhancement. *Med Res Arch*. 2026;14(7). doi:10.18103/mra.2026.0439
108. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell*. 2008;133(5):775-787. doi:10.1016/j.cell.2008.05.009
109. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature*. 2012;488(7410):178-184. doi:10.1038/nature11319
110. Akimbekov NS, Digel I, Sherelkhan DK, Lutfur AB, Razzaque MS. Vitamin D and the host-gut microbiome: a brief overview. *Acta Histochem Cytochem*. 2020;53(3):33-42. doi:10.1267/ahc.20011
111. Raghavan PR. Metadichol: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses in Vitro. *BioMed Res Int*. 2022;2022:1558860. doi:10.1155/2022/1558860

112. Raghavan PR. Metadichol® inhibits zoonotic viruses Nipah, Lassa, and Rabies in vitro: evidence for the VDR-MYC-SP1-GSPT1 axis. *Med Res Arch.* 2026;14(3). doi:10.18103/mra.v14i3.7269
113. Bass JJ, Kazi AA, Deane CS, et al. The mechanisms of skeletal muscle atrophy in response to transient knockdown of the vitamin D receptor in vivo. *J Physiol.* 2021;599(3):963-979. doi:10.1113/JP280652
114. Raghavan PR. Turning VDR Off to Turn Immunity On: Metadichol Derepresses VDBP in Human Monocytes. *Med Res Arch.* 2026;14(7). doi:10.18103/mra.2026.0394
115. Raghavan PR. Metadichol orchestrates pluripotency via nuclear receptors during cellular reprogramming. *Med Res Arch.* 2025;13(6). doi:10.18103/mra.v13i6.6603
116. Jin P, Jiang J, Xie N, et al. Nuclear receptors in health and disease: signaling pathways, metabolic disorders, and therapeutic implications. *Signal Transduct Target Ther.* 2025;10(1):23. doi:10.1038/s41392-024-02270-3
117. Sever R, Glass CK. Signaling by nuclear receptors. *Cold Spring Harb Perspect Biol.* 2013;5(3):a016709. doi:10.1101/cshperspect.a016709
118. Huang P, Chandra V, Bhattacharya A, et al. Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions. *Eur J Med Res.* 2025;30(1):456. doi:10.1186/s40001-025-03073-6
119. Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest.* 2012;122(9):3035-3043. doi:10.1172/JCI60047
120. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. *Endocr Rev.* 2010;31(2):139-170. doi:10.1210/er.2009-0007
121. Bowers J, Terrien J, Clerget-Froidevaux MS, et al. Thyroid hormone signaling and homeostasis during aging. *Endocr Rev.* 2013;34(4):556-589. doi:10.1210/er.2012-1056
122. Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. *Physiol Rev.* 2017;97(3):1045-1087. doi:10.1152/physrev.00024.2016
123. Murphy E. Estrogen signaling and cardiovascular disease. *Circ Res.* 2011;109(6):687-696. doi:10.1161/CIRCRESAHA.110.236687
124. Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. *Endocr Rev.* 2008;29(6):677-696. doi:10.1210/er.2008-0017
125. Villena JA, Kralli A. ERRα: a metabolic function for the oldest orphan. *Trends Endocrinol Metab.* 2008;19(8):269-276. doi:10.1016/j.tem.2008.07.005
126. Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. *Future Med Chem.* 2011;3(5):623-638. doi:10.4155/fmc.11.9.
127. Rogina B, Tissenbaum HA. SIRT1, resveratrol and aging. **Front Genet**. 2024;15:1393181. doi:10.3389/fgene.2024.1393181
128. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. **Nature**. 2006;444(7117):337-342. doi:10.1038/nature05354
129. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend **Saccharomyces cerevisiae** lifespan. **Nature**. 2003;425(6954):191-196. doi:10.1038/nature01960
130. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. **Trends *Pharmacol* Sci**. 2014;35(3):146-154. doi:10.1016/j.tips.2013.12.004
131. Kulkarni AS, Gubbi S, Barzilai N. Benefits of metformin in attenuating the hallmarks of aging. **Cell *Metab**. 2020;32(1):15-30. doi:10.1016/j.cmet.2020.04.001
132. Mohammed I, Hollber M, Calber KS, et al. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. **Front Endocrinol (Lausanne)**. 2021;12:718942. doi:10.3389/fendo.2021.718942
133. Chen X, Liu H, Zhou X, et al. The anti-aging mechanism of metformin: from molecular insights to clinical applications. **Molecules**. 2025;30(4):816. doi:10.3390/molecules30040816
134. Wu L, Zhou B, Oshiro-Rapley N, et al. Metformin as anti-aging therapy: is it for everyone? **Trends Endocrinol *Metab**. 2019;30(11):745-755. doi:10.1016/j.tem.2019.07.015.
135. Johnson SC, Rabinovitch PS, Kaeblerlein M. mTOR is a key modulator of ageing and age-related disease. **Nature**. 2013;493(7432):338-345. doi:10.1038/nature11861

136. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. **J Clin Invest**. 2013;123(3):980-989. doi:10.1172/JCI6409
137. Blagosklonny MV. Rapamycin for longevity: opinion article. **Aging (Albany NY)**. 2019;11(19):8048-8067. doi:10.18632/aging.102355
138. Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer's disease: the rapamycin story. **Exp **Gerontol**. 2015;68:51-58. doi:10.1016/j.exger.2014.12.002
139. Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. **J **Gerontol** **A** Biol Sci Med Sci**. 2016;71(7):841-849. doi:10.1093/gerona/glw090
140. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. **Cell **Metab**. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011
141. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. **GeroScience**. 2023;45(1):29-43. doi:10.1007/s11357-022-00705-1
142. Nadeeshani H, Li J, Ying T, Zhang B, Lu J. Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. **J Adv Res**. 2022;37:267-278. doi:10.1016/j.jare.2021.08.003
143. Kirkland JL, Tchkonina T. Senolytic drugs: from discovery to translation. **J Intern Med**. 2020;288(5):518-536. doi:10.1111/joim.13141
144. Hickson LJ, Langhi Prata LGP, Boez SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. **EBioMedicine**. 2019;47:446-456. doi:10.1016/j.ebiom.2019.08.069
145. Zhu Y, Tchkonina T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. **Aging Cell**. 2015;14(4):644-658. doi:10.1111/accel.12344
146. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. **EBioMedicine**. 2018;36:18-28. doi:10.1016/j.ebiom.2018.09.015
147. Justice JN, Nambiar AM, Tchkonina T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. **EBioMedicine**. 2019;40:554-563. doi:10.1016/j.ebiom.2018.12.052.
148. Alemán CL, Más R, Hernández C, et al. A 12-month study of policosanols oral toxicity in Sprague Dawley rats. *Toxicol Lett*. 1994;70(1):77-87. doi:10.1016/0378-4274(94)90147-3
149. Alemán CL, Más Ferreiro R, Noa Puig M, et al. Carcinogenicity of policosanols in Sprague-Dawley rats: a 24-month study. *Teratog Carcinog Mutagen*. 1994;14(5):239-249. doi:10.1002/tcm.1770140505
150. Raghavan PR. Metadichol-induced expression of circadian clock transcription factors in human fibroblasts. *Med Res Arch*. 2024;12(6). doi:10.18103/mra.v12i6.5371
151. Raghavan PR. SOX Transcription Factor Network Modulation by Metadichol: A Novel Paradigm for Regenerative and Precision Medicine. *Med Res Arch*. 2026;14(1). doi:10.18103/mra.v14i1.7184
152. Caiazzo M, Dell'Anno MT, Dvoretzskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature*. 2011;476(7359):224-227. doi:10.1038/nature10284
153. Raghavan PR. Metadichol Drives Natural Killer Cell Maturation via Interleukin-15 Receptor β -Chain Signaling through Nuclear Factor- κ B-Independent Pathways. *Med Res Arch*. 2026;14(7). doi:10.18103/mra.2026.0434
154. Grunewald M, Kumar S, Sharife H, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. *Science*. 2021;373(6554):eabc8479. doi:10.1126/science.abc8479
155. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature*. 2012;485(7396):109-113. doi:10.1038/nature11083
156. Meyuhas O, Kahan T. The race to decipher the top secrets of TOP mRNAs. *Biochim Biophys Acta*. 2015;1849(7):801-811. doi:10.1016/j.bbagr.2014.08.015
157. Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. *Nat Rev Cancer*. 2018;18(1):51-63. doi:10.1038/nrc.2017.104
158. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. *Genes Dev*. 2006;20(9):1075-1080. doi:10.1101/gad.1399706

159. Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. *Nature*. 2012;487(7405):114-118. doi:10.1038/nature11043
160. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. *Mol Cell Biol*. 2003;23(23):8902-8912. doi:10.1128/MCB.23.23.8902-8912.2003
161. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. *J Biol Chem*. 2004;279(43):44475-44482. doi:10.1074/jbc.M403722200
162. Boria I, Garelli E, Gazda HT, et al. The ribosomal basis of Diamond-Blackfan anemia: mutation and database update. *Hum Mutat*. 2010;31(12):1269-1279. doi:10.1002/humu.21383
163. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. *Nature*. 2008;451(7176):335-339. doi:10.1038/nature06494
164. Ljungstrom V, Cortese D, Young E, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. *Haematologica*. 2016;101(9):1072-1079. doi:10.3324/haematol.2016.145769
165. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. *Immunol Rev*. 2005;205:158-169. doi:10.1111/j.0105-2896.2005.00256.x.
166. Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. *Nat Rev Immunol*. 2019;19(9):573-583. doi:10.1038/s41577-019-0180-1.
167. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. *Immunity*. 2016;44(5):973-988. doi:10.1016/j.immuni.2016.04.020.
168. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. *Blood*. 2003;101(9):3543-3549. doi:10.1182/blood-2002-08-2574.
169. Raghavan PR. Interleukin-15: The Molecule That Was Always There, Waiting to Be Switched On. *Med Res Arch*. 2026;14(7). doi:10.18103/mra.2026.0466
170. Dhanoa BS, Cogliati T, Satish AG, Bruford EA, Friedman JS. Update on the Kelch-like (KLHL) gene family. *Hum Genomics*. 2013;7:13. doi:10.1186/1479-7364-7-13
171. Raghavan PR. Metadichol®, Vitamin C and GULO Gene Expression in Mouse Adipocytes. *Biol Med (Aligarh)*. 2018;10:426. doi:10.4172/0974-8369.1000426
172. Raghavan PR. Metadichol Stimulates Gene Expression Across Mammalian Species: Dose Response Characterization and Implications for Restoring Vitamin C Biosynthesis. *Preprints*. Published online August 2025. doi:10.20944/preprints202508.1935.v1
173. Raghavan PR. Metadichol® and Vitamin C Increase In Vivo, an Open-Label Study. *Vitam Miner*. 2017;6:163. doi:10.4172/2376-1318.1000163
174. Raghavan PR. Metadichol® Induced High Levels of Vitamin C: Case Studies. *Vitam Miner*. 2017;6:169. doi:10.4172/2376-1318.1000169
175. Abegglen LM, Caulin AF, Chan A, et al. Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. *JAMA*. 2015;314(17):1850-1860. doi:10.1001/jama.2015.13134.
176. Sulak M, Fong L, Mika K, et al. TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. *eLife*. 2016;5:e11994. doi:10.7554/eLife.11994.
177. Vazquez JM, Sulak M, Chigurupati S, Lynch VJ. A zombie LIF gene in elephants is upregulated by TP53 to induce apoptosis in response to DNA damage. *Cell Rep*. 2018;24(7):1765-1776. doi:10.1016/j.celrep.2018.07.042.
178. Król W, Machelak W, Zielińska M. GDF11 as a friend or an enemy in the cancer biology? *Biochim Biophys Acta Rev Cancer*. 2023;1878(1):188944. doi:10.1016/j.bbcan.2023.188944.
179. Liu Y, Shao L, Chen K, et al. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. *Onco Targets Ther*. 2018;11:8371-8379. doi:10.2147/OTT.S181870.
180. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. *J Gen Physiol*. 1927;8(6):519-530. doi:10.1085/jgp.8.6.519

181. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
182. Motiwala T, Ghoshal K, Das A, et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. *Oncogene*. 2003;22(41):6319-6331. doi:10.1038/sj.onc.1206750
183. Motiwala T, Kutay H, Ghoshal K, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. *Proc Natl Acad Sci U S A*. 2004;101(38):13844-13849. doi:10.1073/pnas.0405451101
184. Motiwala T, Majumder S, Kutay H, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. *Clin Cancer Res*. 2007;13(11):3174-3181. doi:10.1158/1078-0432.CCR-06-1720
185. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. *Nat Rev Mol Cell Biol*. 2013;14(2):83-97. doi:10.1038/nrm3507
186. Richter K, Haslbeck M, Buchner J. The heat shock response: life on the verge of death. *Mol Cell*. 2010;40(2):253-266. doi:10.1016/j.molcel.2010.10.006
187. Escriva H, Delaunay F, Laudet V. Ligand binding and nuclear receptor evolution. *BioEssays*. 2000;22(8):717-727. doi:10.1002/1521-1878(200008)22:8<717::AID-BIES5>3.0.CO;2-I
188. McCollom TM, Ritter G, Simoneit BR. Lipid synthesis under hydrothermal conditions by Fischer-Tropsch-type reactions. *Orig Life Evol Biosph*. 1999;29(2):153-166. doi:10.1023/a:1006592502746
189. Deamer D. *Assembling Life: How Can Life Begin on Earth and Other Habitable Planets?* Oxford University Press; 2019.
190. Szostak JW, Bartel DP, Luisi PL. Synthesizing life. *Nature*. 2001;409(6818):387-390. doi:10.1038/35053176
191. Flügel RM. *Chirality and Life: A Short Introduction to the Early Phases of Chemical Evolution*. Springer-Verlag; 2011.
192. Rowland O, Domergue F. Plant fatty acyl reductases: enzymes generating fatty alcohols for protective layers with potential for industrial applications. *Plant Sci*. 2012;193-194:28-38. doi:10.1016/j.plantsci.2012.05.002
193. Setlow P. Spore germination. *Curr Opin Microbiol*. 2003;6(6):550-556. doi:10.1016/j.mib.2003.10.001
194. Efimov E, Fedotov V, Malaev L, et al. Somatic mutations impose an entropic upper bound on human lifespan. *npj Aging*. 2026. doi:10.1038/s41514-026-00421-6
195. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. *Signal Transduct Target Ther*. 2022;7(1):391. doi:10.1038/s41392-022-01251-0
196. Calabrese EJ, Mattson MP. How does hormesis impact biology, toxicology, and medicine? *NPJ Aging Mech Dis*. 2017;3:13. doi:10.1038/s41514-017-0013-z
197. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. *Cell*. 2016;165(3):535-550. doi:10.1016/j.cell.2016.03.014

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.